0001564590-20-053848 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2020	Nov. 11, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Registrant Name	Arcadia Biosciences, Inc.
Entity Central Index Key	0001469443
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		10,832,203
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Small Business	true
Extended Transition Period	true
Entity File Number	001-37383
Entity Tax Identification Number	81-0571538
Entity Address, Address Line One	202 Cousteau Place
Entity Address, Address Line Two	Suite 105
Entity Address, City or Town	Davis
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95618
City Area Code	530
Local Phone Number	756-7077
Entity Incorporation, State or Country Code	DE
Trading Symbol	RKDA
Title of 12(b) Security	Common
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 10,201	$ 8,417
Short-term investments		16,915
Accounts receivable	373	602
Inventories, net — current	9,416	1,794
Prepaid expenses and other current assets	1,204	712
Total current assets	21,194	28,440
Restricted cash	2,001
Property and equipment, net	3,484	1,799
Right of use asset	6,013	1,963
Inventories, net — noncurrent	461	364
Goodwill	301
Intangible assets, net	400
Other noncurrent assets	23	8
Total assets	33,877	32,574
Current liabilities:
Accounts payable and accrued expenses	6,711	4,685
Amounts due to related parties	29	40
Debt — current	705	24
Unearned revenue — current		42
Operating lease liability — current	700	611
Other current liabilities	263	306
Total current liabilities	8,408	5,708
Debt — noncurrent	2,548	107
Operating lease liability — noncurrent	5,574	1,497
Common stock warrant liabilities	3,065	14,936
Other noncurrent liabilities	2,280	2,000
Total liabilities	21,875	24,248
Commitments and contingencies (Note 14)
Stockholders’ equity:
Common stock, $0.001 par value—150,000,000 shares authorized as of September 30, 2020 and December 31, 2019; 10,832,203 and 8,646,149 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	51	49
Additional paid-in capital	231,954	214,826
Accumulated other comprehensive income		1
Accumulated deficit	(220,725)	(207,171)
Total Arcadia Biosciences stockholders’ equity	11,280	7,705
Non-controlling interest	722	621
Total stockholders' equity	12,002	8,326
Total liabilities and stockholders’ equity	$ 33,877	$ 32,574

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	10,832,203	8,646,149
Common stock, outstanding	10,832,203	8,646,149

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Total revenues	$ 314,000	$ 392,000	$ 904,000	$ 753,000
Operating expenses:
Research and development	1,762,000	1,931,000	5,999,000	5,387,000
Selling, general and administrative	4,292,000	4,477,000	11,689,000	10,434,000
Total operating expenses	7,895,000	6,585,000	21,151,000	16,145,000
Loss from operations	(7,581,000)	(6,193,000)	(20,247,000)	(15,392,000)
Interest expense	(23,000)	(3,000)	(32,000)	(3,000)
Other income, net		119,000	83,000	339,000
Change in fair value of common stock warrant liabilities	1,130,000	(7,777,000)	6,212,000	(6,790,000)
Loss on extinguishment of warrant liability	(682,000)		(635,000)
Offering costs		(336,000)		(702,000)
Net loss before income taxes	(7,156,000)	(14,190,000)	(14,619,000)	(22,548,000)
Income tax benefit (provision)	(9,000)	3,000	(15,000)	(14,000)
Net loss	(7,165,000)	(14,187,000)	(14,634,000)	(22,562,000)
Net loss attributable to non-controlling interest	(774,000)		(1,081,000)
Net loss attributable to common stockholders	$ (6,391,000)	$ (14,187,000)	$ (13,553,000)	$ (22,562,000)
Net loss per share attributable to common stockholders:
Basic and diluted	$ (0.60)	$ (2.04)	$ (1.42)	$ (4.03)
Weighted-average number of shares used in per share calculations:
Basic and Diluted	10,719,618	6,942,612	9,570,259	5,596,545
Other comprehensive loss, net of tax
Unrealized losses on available-for-sale securities		$ (1,000)	$ (1,000)
Other comprehensive loss		(1,000)	(1,000)
Comprehensive loss attributable to common stockholders	$ (6,391,000)	(14,188,000)	(13,554,000)	$ (22,562,000)
Product
Revenues:
Total revenues	245,000	216,000	630,000	485,000
Operating expenses:
Cost of product revenues	1,841,000	177,000	3,463,000	324,000
License
Revenues:
Total revenues	10,000	17,000	110,000	17,000
Royalty
Revenues:
Total revenues	16,000		58,000
Contract Research And Government Grants
Revenues:
Total revenues	$ 43,000	$ 159,000	$ 106,000	$ 251,000

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	June 2019 Offering [Member]	September 2019 Offering [Member]	June 2018 Warrants [Member]	May 2020 Warrant Transaction [Member]	May 2020 Warrants [Member]	June 2019 Purchase Agreement [Member]	March 2018 PIPE [Member]	July 2020 Warrants [Member]	Common Stock [Member]	Common Stock [Member] June 2019 Offering [Member]	Common Stock [Member] September 2019 Offering [Member]	Common Stock [Member] June 2018 Warrants [Member]	Common Stock [Member] June 2019 Purchase Agreement [Member]	Common Stock [Member] March 2018 PIPE [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] June 2019 Offering [Member]	Additional Paid-In Capital [Member] September 2019 Offering [Member]	Additional Paid-In Capital [Member] June 2018 Warrants [Member]	Additional Paid-In Capital [Member] May 2020 Warrant Transaction [Member]	Additional Paid-In Capital [Member] May 2020 Warrants [Member]	Additional Paid-In Capital [Member] June 2019 Purchase Agreement [Member]	Additional Paid-In Capital [Member] March 2018 PIPE [Member]	Additional Paid-In Capital [Member] July 2020 Warrants [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Non-Controlling Interest [Member]
Stockholders Equity, Beginning Balance at Dec. 31, 2018	$ 12,815									$ 45						$ 191,136									$ (178,366)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2018										4,774,919
Issuance of shares related to employee stock purchase plan	8															8
Issuance of shares related to employee stock purchase plan, Shares										2,500
Stock-based compensation	422															422
Net (loss) income	(12,612)																								(12,612)
Stockholders Equity, Ending Balance at Mar. 31, 2019	633									$ 45						191,566									(190,978)
Stockholders Equity, Ending Balance, Shares at Mar. 31, 2019										4,777,419
Stockholders Equity, Beginning Balance at Dec. 31, 2018	12,815									$ 45						191,136									(178,366)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2018										4,774,919
Net (loss) income	(22,562)
Stockholders Equity, Ending Balance at Sep. 30, 2019	14,233									$ 49						214,423									(200,928)		$ 689
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2019										8,646,149
Stockholders Equity, Beginning Balance at Dec. 31, 2018	12,815									$ 45						191,136									(178,366)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2018										4,774,919
Net (loss) income	(28,900)
Stockholders Equity, Ending Balance at Dec. 31, 2019	8,326									$ 49						214,826									(207,171)	$ 1	621
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2019										8,646,149
Stockholders Equity, Beginning Balance at Mar. 31, 2019	633									$ 45						191,566									(190,978)
Stockholders Equity, Beginning Balance, Shares at Mar. 31, 2019										4,777,419
Issuance of shares							$ 3,303							$ 2								$ 3,301
Issuance of shares, Shares														1,489,575
Issuance of placement agent warrants		$ 198															$ 198
Issuance of shares related to the exercise of warrants		$ 5,269									$ 1						$ 5,268
Issuance of shares related to the exercise of warrants, Shares											1,053,745
Offering costs							$ (487)															$ (487)
Stock-based compensation	389															389
Net (loss) income	4,237																								4,237
Stockholders Equity, Ending Balance at Jun. 30, 2019	13,542									$ 48						200,235									(186,741)
Stockholders Equity, Ending Balance, Shares at Jun. 30, 2019										7,320,739
Issuance of shares related to employee stock purchase plan	10															10
Issuance of shares related to employee stock purchase plan, Shares										6,036
Issuance of shares related to employee stock option exercises	3															3
Issuance of shares related to employee stock option exercises, Shares										546
Reclassification of common stock warrant liability balance with exercise	7,016															7,016
Issuance of shares			$ 6,571									$ 1						$ 6,570
Issuance of shares, Shares												1,318,828
Issuance of placement agent warrants			326															326
Offering costs			$ (796)															$ (796)
Stock-based compensation	1,059															1,059
Unrealized losses on available-for-sale securities	(1)
Non-controlling interest contributions	689																										689
Net (loss) income	(14,187)																								(14,187)
Stockholders Equity, Ending Balance at Sep. 30, 2019	14,233									$ 49						214,423									(200,928)		689
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2019										8,646,149
Stockholders Equity, Beginning Balance at Dec. 31, 2019	8,326									$ 49						214,826									(207,171)	1	621
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2019										8,646,149
Issuance of shares related to employee stock purchase plan	14															14
Issuance of shares related to employee stock purchase plan, Shares										7,946
Stock-based compensation	772															772
Unrealized losses on available-for-sale securities	(1)																									(1)
Non-controlling interest contributions	689																										689
Net (loss) income	2,423																								2,525		(102)
Stockholders Equity, Ending Balance at Mar. 31, 2020	12,223									$ 49						215,612									(204,646)		1,208
Stockholders Equity, Ending Balance, Shares at Mar. 31, 2020										8,654,095
Stockholders Equity, Beginning Balance at Dec. 31, 2019	8,326									$ 49						214,826									(207,171)	$ 1	621
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2019										8,646,149
Unrealized losses on available-for-sale securities	(1)
Net (loss) income	(14,634)
Stockholders Equity, Ending Balance at Sep. 30, 2020	12,002									$ 51						231,954									(220,725)		722
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2020										10,832,203
Stockholders Equity, Beginning Balance at Mar. 31, 2020	12,223									$ 49						215,612									(204,646)		1,208
Stockholders Equity, Beginning Balance, Shares at Mar. 31, 2020										8,654,095
Issuance of shares				$ 5,569									$ 1						$ 5,568
Issuance of shares, Shares													1,392,345
Issuance of investor warrants					$ 4,415															$ 4,415
Issuance of placement agent warrants						$ 215															$ 215
Stock-based compensation	595															595
Non-controlling interest contributions	493																										493
Net (loss) income	(9,893)																								(9,688)		(205)
Stockholders Equity, Ending Balance at Jun. 30, 2020	13,617									$ 50						226,405									(214,334)		1,496
Stockholders Equity, Ending Balance, Shares at Jun. 30, 2020										10,046,440
Issuance of shares related to employee stock purchase plan	37															37
Issuance of shares related to employee stock purchase plan, Shares										11,721
Issuance of shares								$ 2,444							$ 1								$ 2,443
Issuance of shares, Shares															641,416
Issuance of investor warrants									$ 2,059															$ 2,059
Issuance of placement agent warrants									$ 101															$ 101
Stock-based compensation	477															477
Shares of common stock issued at closing of ISI transaction	432															432
Shares of common stock issued at closing of ISI transaction, Shares										132,626
Net (loss) income	(7,165)																								(6,391)		(774)
Stockholders Equity, Ending Balance at Sep. 30, 2020	$ 12,002									$ 51						$ 231,954									$ (220,725)		$ 722
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2020										10,832,203

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (7,165,000)	$ 2,423,000	$ (14,187,000)	$ (12,612,000)	$ (14,634,000)	$ (22,562,000)	$ (28,900,000)
Adjustments to reconcile net loss to cash used in operating activities:
Change in fair value of common stock warrant liabilities	(1,130,000)		7,777,000		(6,212,000)	6,790,000
Loss on extinguishment of warrant liability					635,000
Offering costs			336,000			702,000
Depreciation					395,000	133,000
Lease amortization					745,000	530,000
(Gain) Loss on disposal of equipment					(8,000)	1,000
Net amortization of investment premium					(44,000)	(121,000)
Stock-based compensation					1,844,000	1,870,000
Write-down of inventory and prepaid production costs	1,500,000		0		3,063,000	0
Changes in operating assets and liabilities:
Accounts receivable					229,000	38,000
Unbilled revenue						3,000
Inventories					(9,609,000)	(1,411,000)
Prepaid expenses and other current assets					(1,157,000)	(36,000)
Other noncurrent assets					(15,000)
Accounts payable and accrued expenses					2,026,000	2,425,000
Amounts due to related parties					(11,000)	(1,000)
Other current liabilities					(43,000)	3,000
Unearned revenue					(42,000)	(16,000)
Operating lease payments					(629,000)	(534,000)
Net cash used in operating activities					(23,467,000)	(12,186,000)	(17,200,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment					8,000	1,000
Purchases of property and equipment					(2,038,000)	(878,000)
Acquisitions, net of cash acquired					(500,000)
Purchases of investments					(1,292,000)	(18,458,000)
Proceeds from sales and maturities of investments					18,250,000	18,050,000
Net cash provided by (used in) investing activities					14,428,000	(1,285,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from borrowings					3,108,000
Payments of transaction costs relating to extinguishment of warrant liability					(863,000)
Principal payments on notes payable					(26,000)	(2,000)
Proceeds from the exercise of warrants					9,372,000	5,269,000
Proceeds from ESPP purchases					51,000	21,000
Capital contributions received from non-controlling interest					1,182,000	689,000
Net cash provided by financing activities					12,824,000	22,014,000
Net increase in cash, cash equivalents and restricted cash					3,785,000	8,543,000
Cash, cash equivalents and restricted cash — beginning of period		$ 8,417,000		$ 11,998,000	8,417,000	11,998,000	11,998,000
Cash, cash equivalents and restricted cash — end of period	$ 12,202,000		$ 20,541,000		12,202,000	20,541,000	$ 8,417,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes					1,000	2,000
Cash paid for interest					7,000
NONCASH INVESTING AND FINANCING ACTIVITIES:
Fixed assets acquired with notes payable					37,000	139,000
Offering costs in accounts payable and accrued expenses at end of period						21,000
Reclassification of common stock warrant liability balance with warrant exercises						7,016,000
Right of use assets obtained in exchange for new operating lease liabilities					4,157,000	2,328,000
Purchases of fixed assets included in accounts payable and accrued expenses						6,000
March 2018 Purchase Agreement [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants from Purchase Agreement						10,000,000
June 2019 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from warrant exercises, issuance of common stock and warrants from June 2019 Offering						7,500,000
Payments of offering costs						(663,000)
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock warrants issued to placement agent and included in offering costs						86,000
September 2019 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of offering costs						(776,000)
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock warrants issued to placement agent and included in offering costs						95,000
June 2018 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of offering costs						$ (24,000)
May 2020 Warrant Transaction [Member]
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock warrants issued to placement agent and included in offering costs					215,000
July 2020 Warrant Transaction [Member]
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock warrants issued to placement agent and included in offering costs					$ 101,000

Description of Business and Basis of Presentation

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Description of Business and Basis of Presentation

1. Description of Business and Basis of Presentation

Organization

Arcadia Biosciences, Inc. (the “Company”) was incorporated in Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Phoenix, Arizona, American Falls, Idaho, and Molokai, Hawaii. The Company was reincorporated in Delaware in March 2015.

The Company is a leader in science-based approaches to developing high value crop productivity traits primarily in hemp, wheat, and soybean, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The Company uses state of the art gene-editing technology and advanced breeding techniques to develop these proprietary innovations which are beginning to monetize through a number of methods including seed and grain sales, product extract sales, trait licensing and royalty agreements.

In February 2012, the Company formed Verdeca LLC (“Verdeca,” see Note 6), which is jointly owned with Bioceres, Inc. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative. Verdeca, which is consolidated by the Company, was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies.

On August 9, 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 7) to grow, extract, and sell hemp products. The new partnership, Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales.

The Company is closely monitoring how the spread of the novel coronavirus is affecting its business operations and employees. The Company’s targeted revenues have been adversely impacted as hemp growers have been slower to make decisions to purchase hemp seeds due to economic uncertainty and wheat consumer packaged goods companies have been heavily focused on production over R&D evaluation as demand for staples like pasta and flour have increased. At this time, there is significant uncertainty relating to the trajectory of the novel coronavirus outbreak and impact of related responses. The continued spread of the outbreak may further impact the Company’s business, results of operations, and financial condition.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company, Verdeca and Archipelago.

The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE.

For all periods presented, the Company has determined that it is the primary beneficiary of Verdeca, which is a VIE. Accordingly, the Company consolidates the entity in the condensed consolidated financial statements after eliminating intercompany transactions. The Company evaluates its relationships with its VIEs upon the occurrence of certain significant events that affect the design, structure or other factors pertinent to the primary beneficiary determination. Verdeca LLC had no operations for the three and nine months ended September 30, 2020 and 2019, respectively, and had no assets or liabilities as of September 30, 2020 and December 31, 2019, respectively.

For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates the entity in the condensed consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. Net loss attributable to non-controlling interest of $774,000 and $1,081,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the three and nine months ended September 30, 2020, respectively. The non-controlling partner’s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets as of September 30, 2020.

The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included herein and Management’s Discussion and Analysis of Financial Condition and Results of Operations and the condensed consolidated financial statements and notes thereto for the fiscal year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 25, 2020.

Restricted Cash

Restricted cash consists of funds that are contractually or legally restricted as to usage or withdrawal and have been presented separately from cash and cash equivalents on the condensed consolidated balance sheets.

Liquidity, Capital Resources, and Going Concern

As of September 30, 2020, the Company had an accumulated deficit of $220.7 million, and cash and cash equivalents of $10.2 million. For the nine months ended September 30, 2020, the Company had net losses of $14.6 million and net cash used in operations of $23.5 million. For the twelve months ended December 31, 2019, the Company had net losses of $28.9 million and net cash used in operations of $17.2 million.

With cash and cash equivalents of $10.2 million as of September 30, 2020, the Company believes that its existing cash, cash equivalents and investments will be insufficient to meet its anticipated cash requirements for at least through November 2021, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company may seek to raise additional funds through debt or equity financings, if necessary and available. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company’s stockholders and could have unfavorable terms. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that could restrict operations. If the Company is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned development programs or operations. Any of these actions could materially harm the business, results of operations and financial condition.

As previously disclosed, there is significant uncertainty relating to the trajectory of the novel coronavirus outbreak (“COVID-19”) and impact of related responses. The continued spread of the outbreak could materially harm the Company’s business, results of operations, and financial condition. Due to this uncertainty and plans outside of management’s control, the Company may not be able to achieve and implement such plans within one year after the date that the condensed consolidated financial statements are issued to address the substantial doubt that exists.

Recent Accounting Pronouncements

9 Months Ended

Sep. 30, 2020

Accounting Changes And Error Corrections [Abstract]

Recent Accounting Pronouncements

2. Recent Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. Additionally, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326 in April 2019 and ASU 2019-05, Financial Instruments — Credit Losses (Topic 326) — Targeted Transition Relief in May 2019. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. In November 2019, the FASB issued ASU No. 2019-10, which defers the effective date of ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of ASU No. 2016-13 on the condensed consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-13 Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The amendments affect any entity required to make disclosures about recurring or nonrecurring fair value measurements. The amendments were effective for all entities for fiscal years beginning after December 15, 2019. The Company adopted ASU No. 2018-13 on January 1, 2020 and expanded its disclosures for significant unobservable inputs used to develop Level 3 fair value measurements. There was no impact on the condensed consolidated financial statements. See Note 4.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying other areas of existing guidance. The amendments are effective for all entities for fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of the adoption of ASU No. 2019-12 on the condensed consolidated balance sheets, statements of operations and comprehensive loss, or statements of cash flows.

In April 2020, the FASB issued a staff question-and-answer (“Q&A”) document to respond to frequently asked questions about the accounting for lease concessions related to the effects of the COVID-19 pandemic. Under current GAAP, subsequent changes to lease payments that are not stipulated in the original lease contract are generally accounted for as lease modifications under Topic 842. The Q&A allows companies to make an accounting policy election to not evaluate lease concessions related to the effects of the COVID-19 pandemic as lease modifications. Entities that make this election then need to decide whether to apply the lease modification guidance in ASC 842 to the concession or account for the concession as if it were contemplated as part of the existing contract. The Company has not entered into any lease modifications that provide concessions related to the effects of the COVID-19 pandemic, and therefore has not evaluated its option to make this accounting policy election.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)(2)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)

+ Details

Inventory

9 Months Ended

Sep. 30, 2020

Inventory Disclosure [Abstract]

Inventory

3. Inventory

Inventory costs are tracked on a lot-identified basis and are included as cost of product revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value. The write-downs to inventory are based upon estimates about future demand from the Company’s customers and distributors and market conditions. The Company recorded write-downs of wheat inventories, hemp seed inventories, and prepaid production costs of $1.5 million and $3.1 million for the three and nine months ended September 30, 2020, respectively. The $1.3 million write-down of hemp seed inventories related to Archipelago was due to regulatory changes. See Note 7. The developmental hemp seed varieties which did not meet regulatory and quality specifications are the cause for the additional $176,000 write-down. There were no such write-downs for the three and nine months ended September 30, 2019.

The inventories—current line item on the balance sheet represents inventory forecasted to be sold or used in production in the next 12 months, as of the balance sheet date, and consists primarily of the cost of GoodWheat seed, grain, and flour, GLA oil, and hemp seed. The inventories—noncurrent line item on the balance sheet represents inventory expected to be used in production or sold beyond the next 12 months, as of the balance sheet date, and consists primarily of GoodWheat seed and grain, and GLA oil and seed.

Raw materials inventories consist primarily of the cost to purchase hemp seeds and GLA seed production costs incurred by contracted cooperators. Goods in process inventories consist of costs to process hemp seed, hemp seed production costs incurred by Archipelago, grower fees and related costs for soybeans to be transferred to Verdeca, and GoodWheat seed and grain. Finished goods inventories consist of GoodWheat products, GoodHemp seed and GLA oil that are available for sale.

Inventories, net consist of the following (in thousands):

	September 30, 2020		December 31, 2019
Raw materials	$	36	$	67
Goods in process		4,079		188
Finished goods		5,762		1,903
Inventories	$	9,877	$	2,158

Investments and Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2020

Investments And Fair Value Of Financial Instruments [Abstract]

Investments and Fair Value of Financial Instruments

4. Investments and Fair Value of Financial Instruments

Investments

The Company’s investments are “available-for-sale” investments and are free of trading restrictions. These investments are classified as short-term due to the maturity dates of the investments. The investments are carried at fair value, based on quoted market prices or other readily available market information. Unrealized gains and losses, net of taxes, are included in accumulated other comprehensive income, which is reflected as a separate component of stockholder’s equity in the condensed consolidated balance sheets. Gains and losses are recognized when realized in the condensed consolidated statements of operations and comprehensive loss.

The following tables summarize the amortized cost and fair value of the cash equivalents and investment securities portfolio at September 30, 2020 and December 31, 2019, and the corresponding amounts of unrealized gains and losses recognized in accumulated other comprehensive income:

(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
September 30, 2020
Cash equivalents:
Money market funds	$	8,064	$	—	$	—	$	8,064
Total investments	$	8,064	$	—	$	—	$	8,064

(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
December 31, 2019
Cash equivalents:
Money market funds	$	6,864	$	—	$	—	$	6,864
Commercial paper		900		—		—		900
Short-term investments:
Corporate securities		3,300		—		—		3,300
Treasury bills		1,495		1		—		1,496
Commercial paper		12,119		—		—		12,119
Total investments	$	24,678	$	1	$	—	$	24,679

The Company did not have any investment categories that were in a continuous unrealized loss position for more than twelve months as of September 30, 2020.

As of September 30, 2020, the Company did not have any fixed income securities that were in unrealized loss positions, and therefore has determined that no other-than-temporary impairments associated with credit losses were required to be recognized during the three and nine months ended September 30, 2020.

Fair Value Measurement

Fair value accounting is applied for all assets and liabilities that are recognized or disclosed at fair value in the condensed consolidated financial statements on a recurring basis. Assets and liabilities recorded at fair value in the condensed consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows:

•

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.

•

Level 2 inputs are observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3 inputs are unobservable inputs for the asset or liability.

The fair value of the Company’s financial assets as of September 30, 2020 and December 31, 2019 were as follows:

	Fair Value Measurements at September 30, 2020
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	8,064	$	—	$	—	$	8,064
Total Assets at Fair Value	$	8,064	$	—	$	—	$	8,064

	Fair Value Measurements at December 31, 2019
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	6,864	$	—	$	—	$	6,864
Commercial paper		—		900		—		900
Short-term investments:
Corporate securities		—		3,300		—		3,300
Treasury bills		1,496		—		—		1,496
Commercial paper		—		12,119		—		12,119
Total Assets at Fair Value	$	8,360	$	16,319	$	—	$	24,679

The Company’s financial instruments consist primarily of cash and cash equivalents, restricted cash, accounts receivable, short-term investments, accounts payable, accrued liabilities and debt. For accounts receivable, accounts payable, accrued liabilities, and the current portion of debt the carrying amounts of these financial instruments as of September 30, 2020 and December 31, 2019 were considered representative of their fair values due to their short term to maturity or repayment. The carrying value of the noncurrent portion of debt is considered representative of their fair values due to the recency of their issuance related to the quarter ended September 30, 2020. Cash equivalents are carried at cost, which approximates their fair value.

There were no changes in valuation techniques during 2020 or 2019. The valuation methodologies used for the Company’s instruments measured at fair value and their classification in the valuation hierarchy are summarized below:

•

Money market funds and treasury bills – Investments in money market funds and treasury bills are valued using the market approach and are classified within Level 1.

•

Commercial paper and corporate securities – Investments in commercial paper and corporate securities are valued using the market approach and are classified within Level 2.

•

Contingent liability – A contingent liability resulting from the Anawah acquisition, as described in Note 14, is classified within Level 3. The contingent liability was measured and recorded on a recurring basis as of September 30, 2020 and December 31, 2019 using unobservable quantitative inputs that would impact the Company’s ability and intent to pursue certain specific products developed using technology acquired in the purchase. At September 30, 2020 and December 31, 2019, this liability was included on the condensed consolidated balance sheets as a noncurrent liability.

•

Purchase Agreement common stock warrant liability – The Company has outstanding warrants to purchase common stock that it issued to certain accredited investors and its placement agent on March 22, 2018 (as described in Note 10). The common stock warrants were classified as a liability within Level 3 based on the instrument’s adjustment features and a contingent cash payment feature. At September 30, 2020 and December 31, 2019, this liability was included on the condensed consolidated balance sheets as a noncurrent liability.

•

June 2018, June 2019 and September 2019 Offering common stock warrant liabilities – The Company has outstanding warrants to purchase common stock that it issued to certain accredited investors (as described in Note 10). The common stock warrants are classified as a liability within Level 3 due to a contingent cash payment feature. At September 30, 2020, the June 2019 and September 2019 warrant liabilities were included on the condensed consolidated balance sheets as noncurrent liabilities. At December 31, 2019, the June 2018, June 2019 and September 2019 warrant liabilities were included on the condensed consolidated balance sheets as noncurrent liabilities.

The estimated fair value of the common stock warrant liabilities related to the March 2018 Purchase Agreement, the June 2018 Offering, the June 2019 Offering and the September 2019 Offering (the “warrant liabilities”) were remeasured at September 30, 2020 and December 31, 2019 utilizing the Black-Scholes Model, with the changes recorded on the Company’s condensed consolidated statements of operations and comprehensive loss. The Black-Scholes Model utilizes the following inputs to estimate fair value of an instrument: stock price, expected term, expected volatility, risk-free interest rate, and expected dividend yield. Volatility is considered by the Company to be a significant unobservable input and is calculated using a weighted average of historical stock prices of a combination of the Company and peer companies, due to the lack of sufficient historical data of the Company’s own stock price. A change in the mix or weighting of the peer companies could have resulted in a significantly lower (higher) fair value measurement as of September 30, 2020. Volatility rates used in the measurement of the warrant liabilities ranged from 125.0% to 130.0%, and the weighted average was 127.2%.

The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):

	(Level 3)
(Dollars in thousands)	Common Stock Warrant Liability - March 2018 Purchase Agreement			Common Stock Warrant Liability - June 2018 Offering			Common Stock Warrant Liability - June 2019 Offering			Common Stock Warrant Liability - September 2019 Offering			Contingent Liability		Total
Balance as of December 31, 2019	$	4,579		$	5,444		$	1,993		$	2,920		$	2,000	$	16,936
Change in fair value		(2,155	)		(1,426	)		(1,064	)		(1,567	)		—		(6,212	)
Exercise of warrants (Note 10)		(1,641	)		(4,018	)		—			—			—		(5,659	)
ISI acquisition contingent consideration		—			—			—			—			280		280
Balance as of September 30, 2020	$	783		$	—		$	929		$	1,353		$	2,280	$	5,345

Industrial Seed Innovations Acquisition

9 Months Ended

Sep. 30, 2020

Business Combinations [Abstract]

Industrial Seed Innovations Acquisition

5. Industrial Seed Innovations Acquisition

On August 21, 2020, the Company acquired by merger Industrial Seed Innovations (ISI), an Oregon-based industrial hemp breeding and seed company. As a result of the acquisition, the Company acquired ISI’s commercial and genetic assets, including seed varieties, germplasm library and intellectual property. ISI’s Rogue and Umpqua seed varieties are now part of Arcadia’s portfolio, alongside the Company’s GoodHemp line of genetically superior hemp seeds, transplants, and extracts. The acquisition has significantly broadened and accelerated commercialization of Arcadia’s hemp-related breeding platform, as well as established a breeding research and development facility in the Pacific Northwest, a key production area in the hemp industry.

The purchase price consideration for the acquisition totaled an estimated $1,212,000, of which $500,000 in cash and $432,000, in the form of 132,626 shares of the Company’s common stock, was paid during the third quarter ended September 30, 2020. The remaining amount of $280,000 will be recognized in two annual installments, each of up to 132,626 shares of the Company’s common stock, subject to the achievement of revenue milestones in 2021 and 2022. The cash consideration paid for the acquisition was funded by cash on hand.

For the three months period ended September 30, 2020 no revenues from ISI were recorded, and expenses were immaterial. The pro forma impact of the acquisition to the historical financial results was determined to not be significant.

Acquisition costs are not included as components of consideration transferred and instead are accounted for as expenses in the period in which the costs are incurred. The Company incurred costs related to the ISI acquisition of approximately $67,000 included in selling, general and administrative expenses in the Company's Consolidated Statements of Operations and Comprehensive Loss.

The following table presents the preliminary allocation of the purchase price of ISI assets acquired, based on their relative fair values, which have been assessed during the quarter ended September 30, 2020:

	Purchase Price Allocation
Inventory	$	511
Intangible assets		400
Goodwill		301
Total consideration allocated	$	1,212

The former shareholders of ISI remain responsible for ISI’s pre-acquisition liabilities. Pursuant to the definitive acquisition agreement, the Company entered into a lease agreement with ISI for the use of land, equipment, greenhouses and buildings. The lease was effective upon the execution of the definitive acquisition agreement and has a term of 3 years with the option to renew for three additional 3-year terms.

Variable Interest Entity

9 Months Ended

Sep. 30, 2020

Equity Method Investments And Joint Ventures [Abstract]

Variable Interest Entity

6. Variable Interest Entity

In February 2012, the Company formed Verdeca LLC (“Verdeca”), which is equally owned with Bioceres, Inc. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative owned by approximately 300 shareholders, including some of South America’s largest soybean growers. Verdeca was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies.

The Company determined that a de facto agency relationship between the Company and Bioceres exists. The Company considers qualitative factors in assessing the primary beneficiary which include understanding the purpose and design of the VIE, associated risks that the VIE creates, activities that could be directed by the Company, and the expected relative impact of those activities on the economic performance of the VIE. Based on an evaluation of these factors, the Company concluded that it is the primary beneficiary of Verdeca.

Both the Company and Bioceres incur expenses in support of specific activities, as agreed upon by joint work plans, which apply fair market value to each partner’s activities. Unequal contributions of services are equalized by the partners through cash payments. Verdeca is not the primary obligor for these activities performed by the Company or Bioceres. Under the terms of the joint development agreement, the Company has incurred direct expenses and allocated overhead in the amounts of $240,000 and $340,000, for the three months ended September 30, 2020 and 2019, respectively, and $454,000 and $982,000 for the nine months ended September 30, 2020 and 2019, respectively.

Consolidated Joint Venture

9 Months Ended

Sep. 30, 2020

Equity Method Investments And Joint Ventures [Abstract]

Consolidated Joint Venture

7. Consolidated Joint Venture

On August 9, 2019, the Company and Legacy Ventures Hawaii, LLC, a Nevada limited liability company (“Legacy”), formed Archipelago Ventures Hawaii, LLC, a Delaware limited liability company (“Archipelago”) and entered into a Limited Liability Company Operating Agreement (the “Operating Agreement”). The Company and Legacy formed Archipelago to develop, extract and commercialize hemp-derived products from industrial hemp grown in Hawaii. The Company continued to cultivate hemp through third quarter of 2020 with the intention of producing CBD oil for sale. However, with the recently issued Drug Enforcement Agency (“DEA”) interim final ruling (“IFR”) and the expiration of the Hawaiian Industrial Pilot Program on October 31, 2020, Archipelago’s joint operating committee made the decision to temporarily cease operations in the manner in which it is currently configured. The DEA IFR specifies that should the THC content exceed 0.3% at any point during the extraction process, processers will be considered to be in possession of a Schedule I controlled substance. The Company will continue to monitor the regulatory environment and determine when and in what manner it is feasible and beneficial to re-enter the market. As a result, the Company destroyed the hemp plants that were currently in the ground and disposed of the biomass that had already been harvested, prior to October 31, 2020 as neither would have been able to be processed into CBD oil and remain in compliance with the regulatory framework effective November 1, 2020. The value of the plants and biomass totaled $1.3 million and was written off from inventory to cost of product revenues in the three months ended September 30, 2020.

Pursuant to the Operating Agreement, a joint operating committee consisting of two individuals appointed by the Company and two individuals appointed by Legacy will manage Archipelago. As of September 30, 2020, the Company and Legacy hold 50.75% and 49.25% percentage interests in Archipelago, respectively, and have made capital contributions to Archipelago of $1,927,000 and $1,871,000, respectively, as determined by the joint operating committee. The Operating Agreement includes indemnification rights, non-competition obligations, and certain rights and obligations in connection with the transfer of membership interests, including rights of first refusal.

The Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. Net loss attributable to non-controlling interest of $774,000 and $1,081,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders on the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2020, respectively. Legacy’s equity interests are presented as noncontrolling interests on the condensed consolidated balance sheets. Refer to Note 1 for basis of presentation.

Collaborative Arrangements

9 Months Ended

Sep. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaborative Arrangements

8. Collaborative Arrangements

In August 2017, the Company entered into a collaborative arrangement for the research, development and commercialization of an improved wheat quality trait in North America. This collaborative arrangement is a contractual agreement with Corteva AgriScience (“Corteva”) and involves a joint operating activity where both the Company and Corteva are active participants in the activities of the collaboration. The Company and Corteva participate in the research and development, and the Company has the primary responsibility for the intellectual property strategy while Corteva will generally lead the marketing and commercialization efforts. Both parties are exposed to significant risks and rewards of the collaboration and the agreement includes both cost sharing and profit sharing. The activities are performed with no guarantee of either technological or commercial success.

The Company accounts for research and development (“R&D”) costs in accordance ASC 730, Research and Development, and expenses internal R&D costs as incurred. Third-party R&D costs are expensed when the contracted work has been performed or as milestone results are achieved.

Leases

9 Months Ended

Sep. 30, 2020

Lessee Disclosure [Abstract]

Leases

9. Leases

Operating Leases

As of September 30, 2020, the Company leases office space in Davis, CA, Phoenix, AZ, and Molokai, HI, as well as additional buildings, land and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these short-term leases on a straight-line basis. The Company subleases a portion of the Davis office lease to third parties. During the nine months ended September 30, 2020, the Company entered into three lease amendments that provide for additional office space in Davis, CA, and extend the term through April 2025, with one option to renew for an additional five-year term. The Company expects to exercise its options to renew, and in accordance with ASC 842, accounted for the amendment and expected renewal as a lease modification and remeasured the operating lease liability, resulting in an additional $3.8 million operating lease liability and right of use asset. The Company also entered into a lease amendment for additional parcels of land in Molokai, HI, modified the Molokai office space lease to extend the term by 12 months, and entered into new lease agreements for office equipment, collectively resulting in an additional $0.1 million of operating lease liabilities and right of use assets. During the three months ended September 30, 2020, the Company also entered into a lease amendment for the land and greenhouse in Woodland, CA, modified the Woodland lease to extend the term by 4 years collectively, and entered into a new lease for the premises and equipment related to the purchase of ISI in Oregon with a three-year term, resulting in an additional $0.5 million of operating lease liabilities and right of use assets. There are no finance leases or material leases that have not yet commenced as of September 30, 2020.

Some leases (the Davis office, warehouse, greenhouse and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years. The exercise of lease renewal options is at the Company’s sole discretion.

The Company’s lease agreements do not contain any material variable lease payments, material residual value guarantees or material restrictive covenants. Leases consisted of the following (in thousands):

Leases	Balance Sheet Line Item	September 30, 2020		December 31, 2019
Assets
Operating lease assets	Right of use asset	$	6,013	$	1,963
Total leased assets		$	6,013	$	1,963
Liabilities
Current - Operating	Operating lease liability- current	$	700	$	611
Noncurrent - Operating	Operating lease liability- noncurrent		5,574		1,497
Total leased liabilities		$	6,274	$	2,108

Lease Cost	Classification	For the Three Months Ended September 30, 2020			For the Three Months Ended September 30, 2019			For the Nine Months Ended September 30, 2020			For the Nine Months Ended September 30, 2019
Operating lease cost	SG&A and R&D Expenses	$	261		$	177		$	745		$	529
Short term lease cost (1)	R&D Expenses		109			45			303			138
Short term lease cost	SG&A Expenses		—			—			3			—
Sublease income (2)	SG&A and R&D Expenses		(12	)		(13	)		(34	)		(40	)
Net lease cost		$	358		$	209		$	1,017		$	627

(1)	Short term lease cost included in R&D expenses consists primarily of field trial lease agreements with a lease term of 12 months or less.

(2)	Sublease income is recorded as a credit to lease expense.

Lease Term

and Discount Rate

September 30, 2020

December 31, 2019

Weighted-average remaining

lease term (years)

5.8

2.6

Weighted-average discount rate

6.6

7.0

Private Placement and Registered Direct Offering

9 Months Ended

Sep. 30, 2020

Warrants And Rights Note Disclosure [Abstract]

Private Placement and Registered Direct Offering

10. Private Placement and Registered Direct Offering

Private Placement (2018) and July Warrant Exercise Transaction (2020)

On March 22, 2018, the Company issued 300,752 shares of its common stock (“common stock”) and warrants to purchase up to 300,752 shares of common stock with an initial exercise price equal to $45.75 (the “March 2018 Warrants”), in a private placement (the “March 2018 Private Placement”) in accordance with a securities purchase agreement (the “March 2018 Purchase Agreement”) entered into with certain institutional and accredited investors (collectively, the “Purchasers”) on March 19, 2018. The number of shares of common stock, the number and exercise price of the March 2018 Warrants issued to the Purchasers were subject to adjustments as provided in the March 2018 Purchase Agreement. The March 2018 Warrants are immediately exercisable, subject to certain ownership limitations, and expire five years after the date of issuance.

Following the adjustments as provided in the March 2018 Purchase Agreement, the number of shares issued to the Purchasers was 1,201,634, the total number of shares issuable upon exercise of the March 2018 Warrants was 1,282,832 and the per share exercise price of the March 2018 Warrants was $10.7258. These condensed consolidated financial statements reflect these additional issuances.

The adjustment feature for the common stock and the March 2018 Warrants were determined to be liabilities based on each instrument’s adjustment features and the contingent cash payment feature of the common stock warrants.

The March 2018 Warrant liability was marked-to-market and valued at $0.8 million at September 30, 2020, resulting in income of $0.2 million and income of $2.2 recognized during the three and nine months ended September 30, 2020, respectively. The March 2018 Warrant liability was marked-to-market and valued at $3.8 million at September 30, 2019, resulting in expense of $1.6 million and $1.6 million recognized during the three and nine months ended September 30, 2019, respectively.

On July 8, 2020, pursuant to the terms of a letter agreement entered into on July 6, 2020 (the “transaction date”), an existing accredited investor exercised its March 2018 Warrants (the “July 2020 Warrant Exercise Transaction”) to purchase up to an aggregate of 641,416 shares of the Company’s common stock at a reduced exercise price of $3.975 per share for gross proceeds of $2.6 million. The 641,416 shares of common stock sold in the July 2020 Warrant Exercise Transaction are registered for resale pursuant to a Registration Statement on Form S-3 (File No. 333-224061). The July 2020 Warrant Exercise Transaction closed on July 8, 2020.

As consideration for the exercise of the March 2018 Warrants, the Company issued new unregistered warrants to purchase up to 641,416 shares of common stock (the “July 2020 Warrants”) at an exercise price of $3.85 per share with an exercise period of five and one-half years from the date of issuance.

The aggregate net proceeds received by the Company for the July 2020 Warrant Exercise Transaction were $2.3 million, consisting of gross proceeds of $2.6 million less offering costs of $269,000. The Company currently intends to use the net proceeds from the offering to pay for general corporate expenses.

The March 2018 Warrants were determined to be a liability in accordance with ASC 480, Distinguishing Liabilities from Equity, and ASC 815-40, Derivatives and Hedging – Contracts in Entity’s Own Equity, as the Company is required to make a cash payment to the warrant holders if it fails to make timely filings with the SEC. The July 2020 Warrants do not include the same cash penalty provisions for untimely SEC filings, and therefore were determined to be an equity instrument. The March 2018 Warrants liability was marked-to-market and valued at $1.6 million on July 6, 2020, resulting in income of $2.2 million in the nine months ended September 30, 2020. In connection with the July 2020 Warrant Exercise Transaction, the Company recognized a loss on extinguishment of warrant liability of approximately $682,000 in the nine months ended September 30, 2020. The loss on extinguishment of warrant liability is comprised of the difference between the reacquisition price and the carrying amount of the March 2018 Warrants. The reacquisition price includes the fair value of the 641,416 shares of common stock issued, the fair value of the July 2020 Warrants, and the transaction costs of $0.4 million incurred (see “Offering Costs (July 2020 Warrants)” below). The shares of common stock issued were valued at $2.4 million as of the transaction date. The July 2020 Warrants were valued at $2.1 million which was calculated using the Black-Scholes Model with the following assumptions: volatility of 126 percent, stock price of $3.73 and risk-free rate of 0.30%. The carrying amount of the March 2018 Warrants includes both the fair value of the March 2018 Warrants liability and the cash gross proceeds of $2.6 million received by the Company as result of the exercise of the March 2018 Warrants. The carrying value of the March 2018 Warrants was valued at $1.6 million which was calculated using the Black-Scholes Model with the following assumptions: volatility of 151 percent, stock price of $3.81 and risk-free rate of 0.19%.

The March 2018 Warrants were marked-to-market and valued at $3.8 million at September 30, 2019, resulting in expense of $1.6 million for the nine months ended September 30, 2019.

Offering Costs (July 2020 Warrants)

In connection with the July 2020 Warrant Exercise Transaction, the Company paid to a placement agent an aggregate fee equal to $178,000. The Company also granted warrants to purchase a total of 32,071 shares of common stock (the “July 2020 Placement Agent Warrants”) that have an exercise price per share equal to $4.969 and a term of five and one-half years. The July 2020 Placement Agent Warrants were issued for services performed by the placement agent as part of the Warrant Exercise Transaction and were treated as offering costs. The value of the July 2020 Placement Agent Warrants was determined to be $101,000 using the Black-Scholes Model with input assumptions including the Company’s stock price, expected life of the warrants, stock price volatility determined from the Company’s historical stock prices and the volatility of a peer group, and the risk-free interest rate for the term of the warrants. The Company incurred additional offering costs totaling $91,000 that consist of direct incremental legal, advisory, accounting and filing fees relating to the Warrant Exercise Transaction. The offering costs, inclusive of the July 2020 Placement Agent Warrants, totaled $0.4 million. The value of the July 2020 Placement Agent Warrants of $101,000 was recorded as additional paid in capital in the three months ended September 30, 2020, and the remainder was recorded to loss on extinguishment of warrant liability.

Registration of July Warrant Shares (2020)

On August 13, 2020, the Company filed a registration statement on Form S-3/A (File No. 333-239641) with the SEC to register for resale 32,071 shares of common stock underlying the July 2020 Placement Agent Warrants and 641,416 shares of common stock underlying the July 2020 Warrants.

Registered Direct Offering (2018) and May Warrant Exercise Transaction (2020)

On June 11, 2018, the Company entered into agreements with several institutional and accredited investors (the “June 2018 Purchase Agreement”) for the purchase of 1,392,345 shares of its common stock at a purchase price of $9.93 per share.

Additionally, in a concurrent private placement, the Company issued to the investors unregistered warrants to purchase up to 1,392,345 shares of common stock at a purchase price per warrant of $0.125 (the “June 2018 Warrants”). The June 2018 Warrants have an exercise price of $9.94 per share. Subject to certain ownership limitations, the June 2018 Warrants are exercisable upon issuance and expire five and one-half years after the date of issuance.

On May 18, 2020, pursuant to the terms of letter agreements entered into on May 14, 2020 (the “transaction date”), several existing accredited investors exercised the June 2018 Warrants (the “May 2020 Warrant Exercise Transaction”) to purchase up to an aggregate of 1,392,345 shares of the Company’s common stock at a reduced exercise price of $4.90 per share for gross proceeds of $6.8 million. The 1,392,345 shares of common stock sold in the May 2020 Warrant Exercise Transaction are registered for resale pursuant to a Registration Statement on Form S-1 (File No. 333-229047). The May 2020 Warrant Exercise Transaction closed on May 18, 2020.

As consideration for the exercise of the June 2018 Warrants, the Company issued new unregistered warrants to purchase up to 1,392,345 shares of common stock (the “May 2020 Warrants”) at an exercise price of $4.775 per share with an exercise period of five years from the date of issuance.

The aggregate net proceeds received by the Company for the May 2020 Warrant Exercise Transaction were $6.2 million, consisting of gross proceeds of $6.8 million less offering costs of $594,000. The Company intends to use the net proceeds from this offering to pursue a range of near-term inorganic growth opportunities within the Company’s hemp business unit.

The June 2018 Warrants were determined to be a liability in accordance with ASC 480, Distinguishing Liabilities from Equity, and ASC 815-40, Derivatives and Hedging – Contracts in Entity’s Own Equity, as the Company is required to make a cash payment to the warrant holders if it fails to make timely filings with the SEC. The May 2020 Warrants do not include the same cash penalty provisions for untimely SEC filings, and therefore were determined to be an equity instrument. The June 2018 Warrants liability was marked-to-market and valued at $4.0 million on May 14, 2020, resulting in income of $1.4 million in the nine months ended September 30, 2020. In connection with the May 2020 Warrant Exercise Transaction, the Company recognized a gain on extinguishment of warrant liability of approximately $47,000 in the nine months ended September 30, 2020. The gain on extinguishment of warrant liability is comprised of the difference between the reacquisition price and the carrying amount of the June 2018 Warrants. The reacquisition price includes the fair value of the 1,392,345 shares of common stock issued, the fair value of the May 2020 Warrants, and the transaction costs of $0.8 million incurred (see “Offering Costs (May 2020 Warrants)” below). The shares of common stock issued were valued at $5.6 million as of the transaction date. The May 2020 Warrants were valued at $4.4 million which was calculated using the Black-Scholes Model with the following assumptions: volatility of 128 percent, stock price of $3.81 and risk-free rate of 0.38%. The carrying amount of the June 2018 Warrants includes both the fair value of the June 2018 Warrants liability and the cash proceeds of $6.8 million received by the Company as result of the exercise of the June 2018 Warrants. The carrying value of the June 2018 Warrants was valued at $4.0 million which was calculated using the Black-Scholes Model with the following assumptions: volatility of 140 percent, stock price of $4.00 and risk-free rate of 0.28%.

The June 2018 Warrants were marked-to-market and valued at $4.5 million at September 30, 2019, resulting in expense of $1.9 million and $1.8 million recognized during the three and nine months ended September 30, 2019, respectively.

Offering Costs (May 2020 Warrants)

In connection with the May 2020 Warrant Exercise Transaction, the Company paid to a placement agent an aggregate fee equal to $478,000. The Company also granted warrants to purchase a total of 69,617 shares of common stock (the “May 2020 Placement Agent Warrants”) that have an exercise price per share equal to $6.125 and a term of five years. The May 2020 Placement Agent Warrants were issued for services performed by the placement agent as part of the Warrant Exercise Transaction and were treated as offering costs. The value of the May 2020 Placement Agent Warrants was determined to be $215,000 using the Black-Scholes Model with input assumptions including the Company’s stock price, expected life of the warrants, stock price volatility determined from the Company’s historical stock prices and the volatility of a peer group, and the risk-free interest rate for the term of the warrants. The Company incurred additional offering costs totaling $116,000 that consist of direct incremental legal, advisory, accounting and filing fees relating to the Warrant Exercise Transaction. The offering costs, inclusive of the May 2020 Placement Agent Warrants, totaled $0.8 million. The value of the May 2020 Placement Agent Warrants of $215,000 was recorded as additional paid in capital in the nine months ended September 30, 2020, and the remainder was recorded to gain on extinguishment of warrant liability.

Registration of May Warrant Shares (2020)

On July 2, 2020, the Company filed a registration statement on Form S-3 (File No. 333-239641) with the SEC to register for resale 69,617 shares of common stock underlying the May 2020 Placement Agent Warrants and 1,392,345 shares of common stock underlying the May 2020 Warrants.

Registered Direct Offering (June 2019)

On June 12, 2019, the Company entered into a securities purchase agreement with certain institutional and accredited investors (the “June 2019 Purchase Agreement”) relating to the offering and sale of 1,489,575 shares of its common stock at a purchase price of $4.91.

Additionally, in a concurrent private placement, the Company issued to the investors unregistered warrants to purchase up to 1,489,575 shares of common stock at a purchase price per warrant of $0.125 (the “June 2019 Warrants”). The June 2019 Warrants have an exercise price of $5.00 per share. Subject to certain ownership limitations, the June 2019 Warrants are exercisable upon issuance and expire five and one-half years after the date of issuance.

The June 2019 Warrants were determined to be a liability as they have a contingent cash payment feature. In August and September 2019, investors exercised 1,053,745 warrants. The remaining 435,830 June 2019 Warrants outstanding were marked to market and valued at $0.9 million at September 30, 2020, resulting in income of $0.4 million and income of $1.1 million recognized during the three and nine months ended September 30, 2020, respectively. The June 2019 Warrant liability was marked-to-market and valued at $1.6 million at September 30, 2019, resulting in expense of $5.3 million and $4.5 million recognized during the three and nine months ended September 30, 2019, respectively.

Registered Direct Offering (September 2019)

On September 5, 2019, the Company entered into a securities purchase agreement with certain institutional and accredited investors (the “September 2019 Purchase Agreement”) relating to the offering and sale of 1,318,828 shares of its common stock at a purchase price of $7.52.

Additionally, in a concurrent private placement, the Company issued to the investors unregistered warrants to purchase up to 659,414 shares of common stock at a purchase price per warrant of $0.125 (the “September 2019 Warrants”). The September 2019 Warrants have an exercise price of $7.52 per share. Subject to certain ownership limitations, the September 2019 Warrants are exercisable upon issuance and expire five and one-half years after the date of issuance.

The September 2019 Warrants were determined to be a liability as they have a contingent cash payment feature. The September 2019 Warrants were marked-to-market and valued at $1.4 million at September 30, 2020, resulting in income of $0.5 million and income of $1.6 million recognized during the three and nine months ended September 30, 2020, respectively.

Debt

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Debt

11. Debt

Vehicle Loans

The Company has various vehicle loans that mature in 2024 and have interest rates that range from 7.64% to 8.00%. As of September 30, 2020, the outstanding balance of vehicle loans was $145,000.

Paycheck Protection Program Note

On April 16, 2020, the Company borrowed $1.1 million and entered into a promissory note for the same amount (the “PPP Note”) under the Paycheck Protection Program (“PPP”) that was established under the Coronavirus Aid Relief, and Economic Security Act (“CARES Act”) of 2020. The PPP Note matures on April 16, 2022, bears an interest rate of 1.00% per year, and is payable monthly beginning on November 2, 2020. The Company may prepay the PPP Note at any time prior to maturity with no prepayment penalties. The principal amount of the PPP Note and accrued interest are eligible for forgiveness if the proceeds are used for qualifying expenses, including payroll, rent, and utilities during the eight week period commencing on April 16, 2020. The Company will be obligated to repay any portion of the principal amount of the PPP Note that is not forgiven, together with accrued interest thereon, until such unforgiven portion is paid in full. The Company intends to apply for loan forgiveness within the required timeframe. No assurance is provided that the Company will obtain forgiveness of the PPP Note in whole or in part. As of September 30, 2020, the outstanding balance of the PPP Note was $1.1 million.

Promissory Note

On June 26, 2020, the Company executed a promissory note (the “Note") in the amount of $2.0 million, payable to MidFirst Bank, a federally chartered savings association (the "Lender"). The Note was issued in accordance with the terms of a Loan Agreement dated as of May 18, 2020 entered into by the Company and the Lender (the “Loan Agreement”) in which the Lender agreed to make advances to the Company from time to time, at any amount up to but not to exceed $2.0 million. Pursuant to the Loan Agreement, the Note accrues interest, adjusted monthly, at a rate equal to the greater of (i) 3.25% and (ii) the sum of (a) the quotient of the LIBOR Index divided by (one minus the reserve requirement set by the Federal Reserve), and (b) 2.50%. The Company is required to make monthly interest payments on the Note to the Lender and pay the full principal amount plus any accrued but unpaid interest outstanding under the Note no later than May 18, 2023. The Company and the Lender also entered into a Pledge and Security Agreement dated as of May 18, 2020 whereby the Company agreed to secure the Note by granting a security interest to the Lender for the Company’s deposit account held with and controlled by the Lender. Due to the lender’s control of the deposit account, the balance of $2.0 million is included in restricted cash on the condensed consolidated balance sheets as of September 30, 2020. As of September 30, 2020, the outstanding balance of the Note was $2.0 million.

Maturities of current and noncurrent debt as of September 30, 2020 are as follows (in thousands):

Years ending December 31,	Amounts
Remainder of 2020	$	126
2021		774
2022		285
2023		2,039
2024		29
Thereafter		—
Total	$	3,253

Stock-Based Compensation and Warrants

9 Months Ended

Sep. 30, 2020

Disclosure Of Compensation Related Costs Share Based Payments And Warrants [Abstract]

Stock-Based Compensation and Warrants

12. Stock-Based Compensation and Warrants

Stock Incentive Plans

The Company has two equity incentive plans: the 2006 Stock Plan (“2006 Plan”) and the 2015 Omnibus Equity Incentive Plan (“2015 Plan”).

In 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under terms and provisions established by the Board of Directors. The Company granted non-statutory stock options (“NSOs”) under the 2006 Plan until May 2015, when the 2006 Plan was terminated for future awards. The 2006 Plan continues to govern the terms of options that remain outstanding and were issued under the 2006 Plan. The 2015 Plan became effective in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 shares under the 2006 Plan that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options (“ISOs”), NSOs, restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants. The ISOs and NSOs will be granted at a price per share not less than the fair value at the date of grant. Options granted generally vest over a four-year period; however, the options granted in the third quarter of 2018 vest over a two-year period, vesting monthly on a pro-rated basis. Options granted, once vested, are generally exercisable for up to 10 years after grant.

In June 2019, the shareholders approved an amendment to the Company’s 2015 Plan for a one-time increase to the number of shares of common stock that may be issued under the 2015 Plan by 120,000 shares. As of September 30, 2020, a total of 1,047,188 shares of common stock were reserved for issuance under the 2015 Plan, of which 85,532 shares of common stock are available for future grant. As of September 30, 2020, a total of 19,227 and 961,656 options are outstanding under the 2006 and 2015 Plans, respectively.

A summary of activity under the stock incentive plans is as follows (in thousands, except share data and price per share):

	Shares Subject to Outstanding Options			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
Outstanding — Balance at December 31, 2019		661,701		$	21.60	$	305
Options granted		491,494			4.32
Options exercised		—			—
Options forfeited		(131,849	)		6.39
Options expired		(40,463	)		48.57
Outstanding — Balance at September 30, 2020		980,883		$	13.87	$	1
Vested and expected to vest — September 30, 2020		965,445		$	14.03	$	1
Exercisable —September 30, 2020		540,267		$	21.51	$	—

As of September 30, 2020, there was $1.2 million of unrecognized compensation cost related to unvested stock-based compensation grants that will be recognized over the weighted-average remaining recognition period of 2.7 years.

The fair value of stock option awards to employees, executives, directors, and other service providers was estimated at the date of grant using the Black-Scholes Model with the following weighted-average assumption. There were 491,494 and 186,571 options granted during the nine months ended September 30, 2020 and 2019, respectively.

	Three Months Ended September 30,				Nine Months Ended September 30,
		2020		2019		2020		2019
Expected term (years)		6.01		6.24		6.50		7.13
Expected volatility	230%		99%		133%		99%
Risk-free interest rate	0.38%		1.84%		1.03%		2.05%
Dividend yield		—		—		—		—

Employee Stock Purchase Plan

The Company’s 2015 Employee Stock Purchase Plan (“ESPP”) became effective on May 14, 2015. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount of up to 15% of their eligible compensation through payroll deductions, subject to any plan limitations. The ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of September 30, 2020, the number of shares of common stock reserved for future issuance under the ESPP is 105,036. The ESPP provides for automatic annual increases in the shares available for purchase on January 1 of each year. As of September 30, 2020, 35,056 shares had been issued under the ESPP. The Company recorded $12,200 and $4,300 of stock compensation expense for the three months ended September 30, 2020 and 2019, respectively, and $40,500 and $6,000 for the nine months ended September 30, 2020 and 2019, respectively.

Warrants

As of September 30, 2020, the Company has 4,450,689 common stock warrants outstanding with a weighted average exercise price of $6.31. The expiration of the warrants ranges from July 2021 to December 2025.

In connection with the Series D preferred stock financing in the first half of 2014, the Company issued warrants, exercisable as of the issuance date, to the Series D preferred stock investors to purchase an aggregate of 61,397 shares of common stock at an exercise price of $363.20 per share and to the placement agents to purchase 1,674 shares of common stock at $268.80. Of the 63,071 warrants issued, 1,759 expired on March 28, 2019 and the remaining 61,312 expired in the second quarter of 2019, along with those issued to the placement agents.

As of September 30, 2020, 656,454 common stock warrants are outstanding that were issued in the March 2018 Private Placement. Of the total, 641,416 shares have a purchase price of $10.7258 and the remaining 15,038 common stock warrants have an exercise price of $41.5625. See Note 10.

As of September 30, 2020, 69,617 common stock warrants are outstanding in accordance with the June 2018 Offering, all of which have an exercise price of $12.568. See Note 10.

In connection with a professional services agreement with a non-affiliated third party, executed in April 2019, the Company issued 45,154 warrants (“Service Warrants”) at an exercise price of $6.18. The Service Warrants vest ratably over 12 months and expire in five years from the date of issuance. The Service Warrants are cancelable immediately prior to a change of control subsequent to the termination/expiration of the advisory agreement. The Company also issued 100,000 performance-based warrants (“Performance Warrants”) at an exercise price of $6.18 and vest in 1/6 increments upon the achievement of a qualifying milestone as defined within the agreement. The Performance Warrants expire in five years from the date of issuance and are cancelable immediately prior to a change of control subsequent to the sixth month anniversary of the termination/expiration of the advisory agreement.

The Service and Performance Warrants were determined to be equity instruments. Stock compensation expense associated with the Service Warrants is recognized ratably over the service period (i.e. one-year term). A performance acceleration event was deemed to have been achieved in August 2019, triggering the full vesting of the Performance Warrants. The Company recognized a portion of the Performance Warrants’ stock compensation expense during the third quarter of 2019 as a cumulative adjustment for the period during which services have already been provided. The remaining Performance Warrants expense is being recognized ratably over the remaining service period. For the Service Warrants, $145,000 of stock compensation expense was recognized during the three and nine months ended September 30, 2020 and $56,000 and $100,000 of stock compensation expense was recognized during the three and nine months ended September 30, 2019, respectively.

In June 2019, concurrent with the June 2019 Offering and pursuant to the June 2019 Purchase Agreement, the Company commenced a private placement whereby it issued and sold warrants exercisable for an aggregate of 1,489,575 shares of common stock, which equals 100% of the shares of common stock sold in the June 2019 Offering, with a purchase price of $0.125 per underlying warrant share and with an exercise price of $5.00 per share. The June 2019 Warrants are exercisable upon issuance and will expire five and a half years from the date of issuance. In August and September 2019, investors exercised a portion of the June 2019 Warrants and purchased 1,053,745 shares of common stock. The Company also issued warrants to the placement agents to purchase a total of 74,479 shares of common stock with an exercise price equal to $6.2938. The placement agent warrants are exercisable upon issuance and will expire five years from the date of issuance. As of September 30, 2020, the investors and placement agent hold outstanding warrants to purchase 510,309 shares of common stock warrants issued pursuant to the June 2019 Offering. See Note 10.

In July 2019, the Company issued warrants to purchase 10,000 shares of common stock to an independent contractor at an exercise price of $2.19 and in August 2019, the Company issued warrants to purchase 20,000 shares of common stock to two affiliated third-parties at an exercise price of $1.92. These warrants were determined to be equity instruments and were measured on the grant date using the Black Scholes Model. The warrants issued in July vest ratably over 12 months and expire two years from the date of issuance. As such, stock compensation expense associated with these warrants is recognized ratably over the 12-month service period. The August warrants vested on the issuance date of August 5, 2019 and expire two years from the date of issuance. As such, stock compensation expense associated with the August warrants was recognized as vested on the issuance date. For the warrants issued in July 2019, stock compensation expense of $2,000 and $10,000 was recognized during the three and nine months ended September 30, 2020.

In September 2019, concurrent with the September 2019 Offering and pursuant to the September 2019 Purchase Agreement, the Company commenced a private placement whereby it issued and sold warrants exercisable for an aggregate of 659,414 shares of common stock, which equals 50% of the shares of common stock sold in the September 2019 Offering, with a purchase price of $0.125 per underlying warrant share and with an exercise price of $7.52 per share. The September 2019 Warrants are exercisable upon issuance and will expire five and a half years from the date of issuance. The Company also issued warrants to the placement agents to purchase a total of 65,942 shares of common stock with an exercise price equal to $9.4781. The placement agent warrants are exercisable upon issuance and will expire five years from the date of issuance. As of September 30, 2020, all 725,356 common stock warrants are outstanding that were issued with the September 2019 Offering. See Note 10.

In February 2020, the Company issued warrants to purchase 10,000 shares of common stock to an independent contractor at an exercise price of $4.91. These warrants were determined to be equity instruments and were measured on the grant date using the Black Scholes Model. The warrants vest ratably over 12 months and expire two years from the date of issuance. As such, stock compensation expense associated with these warrants is recognized ratably over the 12-month service period. Stock compensation expense of $9,400 and $28,200 associated with these warrants was recognized during the three and nine months ended September 30, 2020, respectively.

In connection with an extension of the professional services agreement with a non-affiliated third party, executed in April 2019, the Company issued an additional 150,000 warrants to purchase shares of common stock in February 2020 at an exercise price of $4.71. These warrants were determined to be equity instruments and were measured on the grant date using the Black Scholes Model. The warrants vest ratably over 12 months and expire two years from the date of issuance. As such, stock compensation expense associated with these warrants is recognized ratably over the 12-month service period. Stock compensation expense of $135,400 and $406,200 associated with these warrants was recognized during the three and nine months ended September 30, 2020, respectively.

In connection with a professional services agreement with a non-affiliated third party, executed in March 2020, the Company issued warrants to purchase 18,350 shares of common stock at an exercise price of $2.50. The warrants vested on the issuance date and expire in three years from the date of issuance. The warrants are cancelable immediately prior to a change of control subsequent to the termination/expiration of the advisory agreement. These warrants were determined to be equity instruments and were measured on the grant date using the Black Scholes Model. As such, stock compensation expense associated with these warrants was recognized as vested on the issuance date. Stock compensation expense of $0 and $36,700 was recognized during the three and nine months ended September 30, 2020, respectively.

In May 2020, in consideration for the exercise of the June 2018 Warrants in the May 2020 Warrant Exercise Transaction, the Company issued warrants to purchase 1,392,345 shares of common stock at an exercise price of $4.775 per share with an exercise period of five years from the date of issuance. The Company also issued placement agent warrants to purchase a total of 69,617 shares of common stock that have an exercise price per share equal to $6.125 and a term of five years. As of September 30, 2020, all 1,461,962 common stock warrants are outstanding that were issued with the May 2020 Warrant Exercise Transaction. See Note 10.

In July 2020, in consideration for the exercise of the March 2018 Warrants in the July 2020 Warrant Exercise Transaction, the Company issued warrants to purchase 641,416 shares of common stock at an exercise price of $3.85 per share with an exercise period of five and one-half years from the date of issuance. The Company also issued placement agent warrants to purchase a total of 32,071 shares of common stock that have an exercise price per share equal to $4.969 and a term of five and one-half years. As of September 30, 2020, all 673,487 common stock warrants are outstanding that were issued with the July 2020 Warrant Exercise Transaction. See Note 10.

Income Taxes

9 Months Ended

Sep. 30, 2020

Income Tax Disclosure [Abstract]

Income Taxes

13. Income Taxes

Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date income, plus any significant unusual or infrequently occurring items that are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known, or as the tax environment changes.

The interim financial statement provision for income taxes is different from the amounts computed by applying the United States federal statutory income tax rate of 21%. The Company’s effective tax rate was -0.1% and -0.1% for the three and nine months ended September 30, 2020, and was 0.0% and -0.1% for the three and nine months ended September 30, 2019. The difference between the effective tax rate and the federal statutory rate of 21% was primarily due to the full valuation allowance recorded on the Company’s net deferred tax assets and foreign withholding taxes.

The Company experienced an ownership change under IRC Section 382 as a result of the common shares issued in connection with the June 2018 Offering. This ownership change limited the Company’s ability to utilize its net operating loss carryforwards prior to expiration and certain net operating loss carryforwards were written off as a result. The Company is currently conducting additional analysis regarding the valuation of the Company at the time of the ownership change to assess what, if any, portion of the limitation may be reversed. Any adjustment to the amount of limitation will not impact the deferred tax asset balance due to the full valuation allowance.

During the nine months ended September 30, 2020, there were no material changes to the Company’s uncertain tax positions.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Commitment and Contingencies

9 Months Ended

Sep. 30, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

14. Commitments and Contingencies

Leases

The Company leases office and laboratory space, greenhouse space, grain storage bins, warehouse space, farmland, and equipment under operating lease agreements having initial lease terms ranging from one to five years, including certain renewal options available to the Company at market rates. The Company also leases land for field trials on a short-term basis. See Note 9.

Contingent Liability Related to the Anawah Acquisition

On June 15, 2005, the Company completed its agreement and plan of merger and reorganization with Anawah, Inc. (“Anawah”), to purchase the food and agricultural research company through a non-cash stock purchase. Pursuant to the merger with Anawah, and in accordance with the ASC 805 - Business Combinations, the Company incurred a contingent liability not to exceed $5.0 million. This liability represents amounts to be paid to Anawah’s previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain products developed using technology acquired in the purchase. As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs, thus, the contingent liability was reduced to $3.0 million. During the third quarter of 2016, one of the programs previously accrued for was abandoned and another program previously abandoned was reactivated. During the fourth quarter of 2019, the Company determined that one of the technologies was no longer active and decided to abandon the previously accrued program. As a result, the Company recognized a gain of $1.0 million in the consolidated statements of operations and comprehensive loss. As of September 30, 2020, the Company continues to pursue two development programs using this technology and believes that the contingent liability is probable. As a result, $2.0 million remains on the condensed consolidated balance sheets as an other noncurrent liability.

Contingent Liability Related to the ISI Acquisition

On August 21, 2020, the Company acquired by merger Industrial Seed Innovations (ISI), an Oregon-based industrial hemp breeding and seed company. A portion of the purchase price consideration for the acquisition in the amount of $280,000 will be recognized in two annual installments, each of up to 132,626 shares of the Company’s common stock, subject to the achievement of revenue milestones in 2021 and 2022. See Note 5.

Contracts

The Company has entered into a non-cancelable agreement with an unrelated party to provide research and development services. The agreement requires the Company to pay certain minimum funding commitments. The following table sets forth the minimum funding requirements under this agreement as of September 30, 2020 (in thousands):

Years ending December 31,	Amounts
Remainder of 2020	$	500
2021		750
2022		—
2023		—
2024		—
Thereafter		—
Total	$	1,250

Net Loss per Share

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Net Loss per Share

15. Net Loss per Share

Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per share is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants.

Securities that were not included in the diluted per share calculations because they would have been anti-dilutive were as follows:

	For the Three Months Ended September 30,			For the Nine Months Ended September 30,
		2020	2019		2020	2019
Options to purchase common stock		980,883	691,001		980,883	691,001
Warrants to purchase common stock		4,450,689	4,170,651		4,450,689	4,170,651
Total		5,431,572	4,861,652		5,431,572	4,861,652

The following table sets forth the computation of basic and diluted net loss per common share (in thousands, except share and per share amounts):

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
		2020			2019			2020			2019
Net loss per share - Basic
Numerator:
Net loss attributable to common stockholders	$	(6,391	)	$	(14,187	)	$	(13,553	)	$	(22,562	)
Denominator:
Weighted average number of common shares outstanding		10,719,618			6,942,612			9,570,259			5,596,545
Basic net loss per share attributable to common stockholders:	$	(0.60	)	$	(2.04	)	$	(1.42	)	$	(4.03	)
Net loss per share - Diluted
Numerator:
Net loss attributable to common stockholders	$	(6,391	)	$	(14,187	)	$	(13,553	)	$	(22,562	)
Denominator:
Weighted average number of common shares outstanding		10,719,618			6,942,612			9,570,259			5,596,545
Effect of dilutive stock options		—			—			—			—
Effect of dilutive warrants		—			—			—			—
Weighted average number of common shares outstanding - diluted		10,719,618			6,942,612			9,570,259			5,596,545
Diluted net loss per share attributable to common stockholders:	$	(0.60	)	$	(2.04	)	$	(1.42	)	$	(4.03	)

Related-Party Transactions

9 Months Ended

Sep. 30, 2020

Related-Party Transactions

16. Related-Party Transactions

The Company’s related parties include Moral Compass Corporation (“MCC”) and the John Sperling Foundation (“JSF”). The rights to the intellectual property owned by Blue Horse Labs, Inc. (“BHL”) were assigned to its sole shareholder, the John Sperling Revocable Trust (“JSRT”) due to BHL’s dissolution and then subsequently to JSF. JSF is deemed a related party of the Company because MCC, the Company’s largest stockholder, and JSF share common officers and directors.

JSF receives a single digit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding originally from BHL. Royalty fees due to JSF were $29,000 and $40,000 as of September 30, 2020 and December 31, 2019, respectively, and are included in the condensed consolidated balance sheets as amounts due to related parties.

The Company currently leases land on the island of Molokai, Hawaii from an entity owned by Kevin Comcowich, the Chair of the Company’s Board of Directors, and his wife. The Company grows hemp on this land to support the operations of its joint venture Archipelago Ventures Hawaii. The original lease was executed in February 2019, covers 10 acres of land, has a term of two years and provides for rent payments of $1,200 per acre per year. The Company engaged a third-party contractor to construct a fence on the property to adhere to the rules of the hemp pilot program. Out of pocket costs to build this fence were approximately $126,400. Mr. Comcowich supplied materials to the contractor and received payments from the contractor totaling approximately $44,000. In March and April 2020, the Company entered into two lease amendments for two additional 10-acre parcels and two additional 15-acre parcels, at the same lease rate of $1,200 per acre per year, and with a term of two years. The Company made lease payments in the amount of $36,000 and $84,000 for the three and nine months ended September 30, 2020, respectively.

Subsequent Events

9 Months Ended

Sep. 30, 2020

Subsequent Events [Abstract]

Subsequent Events

17. Subsequent Events

Verdeca LLC Sale Transaction

On November 12, 2020, Arcadia Biosciences, Inc. (the “Company”) entered into a Master Transaction Agreement (the “Agreement”) with Bioceres Crop Solutions Corp. (“BIOX”) pursuant to which (i) the Company sold all of its memberships interests it owned in Verdeca, LLC (“Verdeca”) to Bioceres, Inc., a wholly owned subsidiary of BIOX, and (ii) the Company and BIOX entered into a license agreement for certain intellectual property rights, including rights to the Company’s HB4 soybean trait and its GoodWheat portfolio of specialty wheat products in South and Central America. Prior to the transaction, Verdeca was equally owned by the Company and Bioceres, Inc.

In consideration for the sale of the membership interests in Verdeca and entering into the license agreement, on November 12, 2020, BIOX paid the Company $5,000,000 in cash and issued the Company 1,875,000 shares of BIOX common stock. BIOX will also pay the Company an additional (i) $1,000,000 payable in five equal monthly payments beginning on December 12, 2020 for transaction expenses and fees and (ii) $2,000,000 payable in four equal quarterly payments with the first payment commencing within thirty days of either BIOX reaching commercial plantings of at least 200,000 hectares of HB4 soybeans or if China approves the HB4 soybean trait for “food and feed”. In addition to the above payments, BIOX will also pay the Company quarterly royalty payments equal to six percent (6%) for the net revenues BIOX, or its affiliates, receive from HB4 soybean sales and twenty-five percent (25%) from wheat sales; provided that royalty payments for HB4 soybeans shall not exceed $10,000,000.

The Company agreed not to sell or transfer any shares of BIOX common stock it received in this transaction for a period of 180 days without the prior written consent of BIOX, subject to certain exceptions allowing the Company to pledge shares to a lender as collateral. In addition, by December 12, 2020, the Company is required to seek consents from certain third parties who have right of first refusal or other similar rights to the traits being licensed by the Company to BIOX. If a third party exercises their rights of first refusal on the same terms and conditions as agreed upon by BIOX, then the Company has an option to pay BIOX $5,000,000 or 625,000 shares of BIOX common stock. Upon such payment, BIOX shall have no further rights to such trait which was subject to the right of first refusal. The Company entered into a pledge and security agreement with BIOX for the 625,000 shares of BIOX common stock that are subject to the potential clawback.

Description of Business and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Organization	Organization Arcadia Biosciences, Inc. (the “Company”) was incorporated in Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Phoenix, Arizona, American Falls, Idaho, and Molokai, Hawaii. The Company was reincorporated in Delaware in March 2015. The Company is a leader in science-based approaches to developing high value crop productivity traits primarily in hemp, wheat, and soybean, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The Company uses state of the art gene-editing technology and advanced breeding techniques to develop these proprietary innovations which are beginning to monetize through a number of methods including seed and grain sales, product extract sales, trait licensing and royalty agreements. In February 2012, the Company formed Verdeca LLC (“Verdeca,” see Note 6), which is jointly owned with Bioceres, Inc. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative. Verdeca, which is consolidated by the Company, was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies. On August 9, 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 7) to grow, extract, and sell hemp products. The new partnership, Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales. The Company is closely monitoring how the spread of the novel coronavirus is affecting its business operations and employees. The Company’s targeted revenues have been adversely impacted as hemp growers have been slower to make decisions to purchase hemp seeds due to economic uncertainty and wheat consumer packaged goods companies have been heavily focused on production over R&D evaluation as demand for staples like pasta and flour have increased. At this time, there is significant uncertainty relating to the trajectory of the novel coronavirus outbreak and impact of related responses. The continued spread of the outbreak may further impact the Company’s business, results of operations, and financial condition.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company, Verdeca and Archipelago. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Verdeca, which is a VIE. Accordingly, the Company consolidates the entity in the condensed consolidated financial statements after eliminating intercompany transactions. The Company evaluates its relationships with its VIEs upon the occurrence of certain significant events that affect the design, structure or other factors pertinent to the primary beneficiary determination. Verdeca LLC had no operations for the three and nine months ended September 30, 2020 and 2019, respectively, and had no assets or liabilities as of September 30, 2020 and December 31, 2019, respectively. For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates the entity in the condensed consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. Net loss attributable to non-controlling interest of $774,000 and $1,081,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the three and nine months ended September 30, 2020, respectively. The non-controlling partner’s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets as of September 30, 2020. The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included herein and Management’s Discussion and Analysis of Financial Condition and Results of Operations and the condensed consolidated financial statements and notes thereto for the fiscal year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 25, 2020.
Restricted Cash	Restricted Cash Restricted cash consists of funds that are contractually or legally restricted as to usage or withdrawal and have been presented separately from cash and cash equivalents on the condensed consolidated balance sheets.
Liquidity, Capital Resources, and Going Concern	Liquidity, Capital Resources, and Going Concern As of September 30, 2020, the Company had an accumulated deficit of $220.7 million, and cash and cash equivalents of $10.2 million. For the nine months ended September 30, 2020, the Company had net losses of $14.6 million and net cash used in operations of $23.5 million. For the twelve months ended December 31, 2019, the Company had net losses of $28.9 million and net cash used in operations of $17.2 million. With cash and cash equivalents of $10.2 million as of September 30, 2020, the Company believes that its existing cash, cash equivalents and investments will be insufficient to meet its anticipated cash requirements for at least through November 2021, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company may seek to raise additional funds through debt or equity financings, if necessary and available. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company’s stockholders and could have unfavorable terms. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that could restrict operations. If the Company is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned development programs or operations. Any of these actions could materially harm the business, results of operations and financial condition. As previously disclosed, there is significant uncertainty relating to the trajectory of the novel coronavirus outbreak (“COVID-19”) and impact of related responses. The continued spread of the outbreak could materially harm the Company’s business, results of operations, and financial condition. Due to this uncertainty and plans outside of management’s control, the Company may not be able to achieve and implement such plans within one year after the date that the condensed consolidated financial statements are issued to address the substantial doubt that exists.

Inventory (Tables)

9 Months Ended

Sep. 30, 2020

Inventory Disclosure [Abstract]

Summary of Inventories

Inventories, net consist of the following (in thousands):

	September 30, 2020		December 31, 2019
Raw materials	$	36	$	67
Goods in process		4,079		188
Finished goods		5,762		1,903
Inventories	$	9,877	$	2,158

Investments and Fair Value of Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2020

Investments And Fair Value Of Financial Instruments [Abstract]

Summary of Amortized Cost and Fair Value of the Cash Equivalents and Available-For-Sale Investment Securities Portfolio

(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
September 30, 2020
Cash equivalents:
Money market funds	$	8,064	$	—	$	—	$	8,064
Total investments	$	8,064	$	—	$	—	$	8,064

(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
December 31, 2019
Cash equivalents:
Money market funds	$	6,864	$	—	$	—	$	6,864
Commercial paper		900		—		—		900
Short-term investments:
Corporate securities		3,300		—		—		3,300
Treasury bills		1,495		1		—		1,496
Commercial paper		12,119		—		—		12,119
Total investments	$	24,678	$	1	$	—	$	24,679

Summary of Fair Value of Financial Assets

The fair value of the Company’s financial assets as of September 30, 2020 and December 31, 2019 were as follows:

	Fair Value Measurements at September 30, 2020
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	8,064	$	—	$	—	$	8,064
Total Assets at Fair Value	$	8,064	$	—	$	—	$	8,064

	Fair Value Measurements at December 31, 2019
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	6,864	$	—	$	—	$	6,864
Commercial paper		—		900		—		900
Short-term investments:
Corporate securities		—		3,300		—		3,300
Treasury bills		1,496		—		—		1,496
Commercial paper		—		12,119		—		12,119
Total Assets at Fair Value	$	8,360	$	16,319	$	—	$	24,679

Summary of Changes in Fair Value of Liabilities

The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):

	(Level 3)
(Dollars in thousands)	Common Stock Warrant Liability - March 2018 Purchase Agreement			Common Stock Warrant Liability - June 2018 Offering			Common Stock Warrant Liability - June 2019 Offering			Common Stock Warrant Liability - September 2019 Offering			Contingent Liability		Total
Balance as of December 31, 2019	$	4,579		$	5,444		$	1,993		$	2,920		$	2,000	$	16,936
Change in fair value		(2,155	)		(1,426	)		(1,064	)		(1,567	)		—		(6,212	)
Exercise of warrants (Note 10)		(1,641	)		(4,018	)		—			—			—		(5,659	)
ISI acquisition contingent consideration		—			—			—			—			280		280
Balance as of September 30, 2020	$	783		$	—		$	929		$	1,353		$	2,280	$	5,345

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Industrial Seed Innovations Acquisition (Tables)

9 Months Ended

Sep. 30, 2020

Business Combinations [Abstract]

Schedule of Preliminary Allocation of the Purchase Price of ISI Assets Acquired Based on Fair Values

	Purchase Price Allocation
Inventory	$	511
Intangible assets		400
Goodwill		301
Total consideration allocated	$	1,212

Leases (Tables)

9 Months Ended

Sep. 30, 2020

Lessee Disclosure [Abstract]

Schedule of Leases

Leases consisted of the following (in thousands):

Leases	Balance Sheet Line Item	September 30, 2020		December 31, 2019
Assets
Operating lease assets	Right of use asset	$	6,013	$	1,963
Total leased assets		$	6,013	$	1,963
Liabilities
Current - Operating	Operating lease liability- current	$	700	$	611
Noncurrent - Operating	Operating lease liability- noncurrent		5,574		1,497
Total leased liabilities		$	6,274	$	2,108

Lease Cost	Classification	For the Three Months Ended September 30, 2020			For the Three Months Ended September 30, 2019			For the Nine Months Ended September 30, 2020			For the Nine Months Ended September 30, 2019
Operating lease cost	SG&A and R&D Expenses	$	261		$	177		$	745		$	529
Short term lease cost (1)	R&D Expenses		109			45			303			138
Short term lease cost	SG&A Expenses		—			—			3			—
Sublease income (2)	SG&A and R&D Expenses		(12	)		(13	)		(34	)		(40	)
Net lease cost		$	358		$	209		$	1,017		$	627

(1)	Short term lease cost included in R&D expenses consists primarily of field trial lease agreements with a lease term of 12 months or less.

(2)	Sublease income is recorded as a credit to lease expense.

Lease Term

and Discount Rate

September 30, 2020

December 31, 2019

Weighted-average remaining

lease term (years)

5.8

2.6

Weighted-average discount rate

6.6

7.0

Debt (Tables)

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Schedule of Maturities of Current and Noncurrent Debt

Maturities of current and noncurrent debt as of September 30, 2020 are as follows (in thousands):

Years ending December 31,	Amounts
Remainder of 2020	$	126
2021		774
2022		285
2023		2,039
2024		29
Thereafter		—
Total	$	3,253

Stock-Based Compensation and Warrants (Tables)

9 Months Ended

Sep. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Activity Under Stock Incentive Plans

A summary of activity under the stock incentive plans is as follows (in thousands, except share data and price per share):

	Shares Subject to Outstanding Options			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
Outstanding — Balance at December 31, 2019		661,701		$	21.60	$	305
Options granted		491,494			4.32
Options exercised		—			—
Options forfeited		(131,849	)		6.39
Options expired		(40,463	)		48.57
Outstanding — Balance at September 30, 2020		980,883		$	13.87	$	1
Vested and expected to vest — September 30, 2020		965,445		$	14.03	$	1
Exercisable —September 30, 2020		540,267		$	21.51	$	—

Weighted-Average Fair Value Assumption of Stock Option Awards

	Three Months Ended September 30,				Nine Months Ended September 30,
		2020		2019		2020		2019
Expected term (years)		6.01		6.24		6.50		7.13
Expected volatility	230%		99%		133%		99%
Risk-free interest rate	0.38%		1.84%		1.03%		2.05%
Dividend yield		—		—		—		—

Commitment and Contingencies (Tables)

9 Months Ended

Sep. 30, 2020

Commitments And Contingencies Disclosure [Abstract]

Schedule of Minimum Funding Requirements Under Non-Cancelable Agreement

The following table sets forth the minimum funding requirements under this agreement as of September 30, 2020 (in thousands):

Years ending December 31,	Amounts
Remainder of 2020	$	500
2021		750
2022		—
2023		—
2024		—
Thereafter		—
Total	$	1,250

Net Loss per Share (Tables)

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Schedule of Securities Not Included in Diluted per Share Calculations

Securities that were not included in the diluted per share calculations because they would have been anti-dilutive were as follows:

	For the Three Months Ended September 30,			For the Nine Months Ended September 30,
		2020	2019		2020	2019
Options to purchase common stock		980,883	691,001		980,883	691,001
Warrants to purchase common stock		4,450,689	4,170,651		4,450,689	4,170,651
Total		5,431,572	4,861,652		5,431,572	4,861,652

Summary of Computation of Basic and Diluted Net Loss Per Common Share

The following table sets forth the computation of basic and diluted net loss per common share (in thousands, except share and per share amounts):

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
		2020			2019			2020			2019
Net loss per share - Basic
Numerator:
Net loss attributable to common stockholders	$	(6,391	)	$	(14,187	)	$	(13,553	)	$	(22,562	)
Denominator:
Weighted average number of common shares outstanding		10,719,618			6,942,612			9,570,259			5,596,545
Basic net loss per share attributable to common stockholders:	$	(0.60	)	$	(2.04	)	$	(1.42	)	$	(4.03	)
Net loss per share - Diluted
Numerator:
Net loss attributable to common stockholders	$	(6,391	)	$	(14,187	)	$	(13,553	)	$	(22,562	)
Denominator:
Weighted average number of common shares outstanding		10,719,618			6,942,612			9,570,259			5,596,545
Effect of dilutive stock options		—			—			—			—
Effect of dilutive warrants		—			—			—			—
Weighted average number of common shares outstanding - diluted		10,719,618			6,942,612			9,570,259			5,596,545
Diluted net loss per share attributable to common stockholders:	$	(0.60	)	$	(2.04	)	$	(1.42	)	$	(4.03	)

Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Accounting Policies [Line Items]
VIEs Operations	$ (7,581,000)			$ (6,193,000)			$ (20,247,000)	$ (15,392,000)
Net loss attributable to non-controlling interest	(774,000)						(1,081,000)
Accumulated deficit	(220,725,000)						(220,725,000)		$ (207,171,000)
Cash and cash equivalents	10,201,000						10,201,000		8,417,000
Net (loss) income	(7,165,000)	$ (9,893,000)	$ 2,423,000	(14,187,000)	$ 4,237,000	$ (12,612,000)	(14,634,000)	(22,562,000)	(28,900,000)
Net cash used in operations							(23,467,000)	(12,186,000)	(17,200,000)
Verdeca LLC [Member]
Accounting Policies [Line Items]
VIEs Operations	0			$ 0			0	$ 0
VIEs assets or liabilities	$ 0						$ 0		$ 0

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

Recent Accounting Pronouncements - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2020
Accounting Changes And Error Corrections [Abstract]
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201813Member
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 01, 2020

- Definition

Indicates amendment to accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)

+ Details

- Definition

Indicates (true false) whether accounting standards update was adopted.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (a)

+ Details

- Definition

Date accounting standards update was adopted, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (a)

+ Details

Inventory - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
Inventory - Additional Information (Detail) - USD ($)	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Inventory Current And Noncurrent [Line Items]
Write-downs of wheat inventories, hemp seed inventories, and prepaid production	$ 1,500,000	$ 0	$ 3,063,000	$ 0
Archipelago
Inventory Current And Noncurrent [Line Items]
Write-down of hemp seed inventories	1,300,000
Additional write-down of hemp seed inventories	$ 176,000

Inventory - Summary of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 36	$ 67
Goods in process	4,079	188
Finished goods	5,762	1,903
Inventories	$ 9,877	$ 2,158

Investments and Fair Value of Financial Instruments - Summary of Amortized Cost and Fair Value of the Cash Equivalents and Available-For-Sale Investment Securities Portfolio (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 8,064	$ 24,678
Unrealized Gains	0	1
Unrealized Losses	0	0
Fair Value	8,064	24,679
Cash Equivalents [Member] \| Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	8,064	6,864
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	$ 8,064	6,864
Cash Equivalents [Member] \| Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		900
Unrealized Gains		0
Unrealized Losses		0
Fair Value		900
Short-term Investments [Member] \| Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		12,119
Unrealized Gains		0
Unrealized Losses		0
Fair Value		12,119
Short-term Investments [Member] \| Treasury Bills [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		1,495
Unrealized Gains		1
Unrealized Losses		0
Fair Value		1,496
Short-term Investments [Member] \| Corporate Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		3,300
Unrealized Gains		0
Unrealized Losses		0
Fair Value		$ 3,300

Investments and Fair Value of Financial Instruments - Additional Information (Detail)	Sep. 30, 2020 USD ($) Security
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Investment in continuous unrealized loss position for more than twelve months	$ 0
Number of fixed income securities in unrealized loss position \| Security	0
Other-than-temporary impairments associated with credit losses required to be recognized	$ 0
Minimum [Member] \| Measurement Input, Price Volatility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrants, measurement input	125.0
Maximum [Member] \| Measurement Input, Price Volatility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrants, measurement input	130.0
Weighted Average [Member] \| Measurement Input, Price Volatility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrants, measurement input	127.2

Investments and Fair Value of Financial Instruments - Summary of Fair Value of Financial Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Assets at Fair Value
Total Assets at Fair Value	$ 8,064	$ 24,679
Treasury Bills [Member]
Assets at Fair Value
Short-term investments		1,496
Level 1 [Member]
Assets at Fair Value
Total Assets at Fair Value	8,064	8,360
Level 1 [Member] \| Treasury Bills [Member]
Assets at Fair Value
Short-term investments		1,496
Level 2 [Member]
Assets at Fair Value
Total Assets at Fair Value	0	16,319
Level 2 [Member] \| Treasury Bills [Member]
Assets at Fair Value
Short-term investments		0
Level 3 [Member]
Assets at Fair Value
Total Assets at Fair Value	0	0
Level 3 [Member] \| Treasury Bills [Member]
Assets at Fair Value
Short-term investments		0
Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	8,064	6,864
Money Market Funds [Member] \| Level 1 [Member]
Assets at Fair Value
Cash equivalents	8,064	6,864
Money Market Funds [Member] \| Level 2 [Member]
Assets at Fair Value
Cash equivalents	0	0
Money Market Funds [Member] \| Level 3 [Member]
Assets at Fair Value
Cash equivalents	$ 0	0
Commercial Paper [Member]
Assets at Fair Value
Cash equivalents		900
Short-term investments		12,119
Commercial Paper [Member] \| Level 1 [Member]
Assets at Fair Value
Cash equivalents		0
Short-term investments		0
Commercial Paper [Member] \| Level 2 [Member]
Assets at Fair Value
Cash equivalents		900
Short-term investments		12,119
Commercial Paper [Member] \| Level 3 [Member]
Assets at Fair Value
Cash equivalents		0
Short-term investments		0
Corporate Securities [Member]
Assets at Fair Value
Short-term investments		3,300
Corporate Securities [Member] \| Level 1 [Member]
Assets at Fair Value
Short-term investments		0
Corporate Securities [Member] \| Level 2 [Member]
Assets at Fair Value
Short-term investments		3,300
Corporate Securities [Member] \| Level 3 [Member]
Assets at Fair Value
Short-term investments		$ 0

Investments and Fair Value of Financial Instruments - Summary of Changes in Fair Value of Liabilities (Detail) - Level 3 [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2020 USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2019	$ 16,936
Change in fair value	(6,212)
Exercise of warrants (Note 10)	(5,659)
ISI acquisition contingent consideration	280
Balance as of September 30, 2020	5,345
Common Stock Warrant Liability [Member] \| Purchase Agreement [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2019	4,579
Change in fair value	(2,155)
Exercise of warrants (Note 10)	(1,641)
ISI acquisition contingent consideration	0
Balance as of September 30, 2020	783
Common Stock Warrant Liability [Member] \| June 2018 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2019	5,444
Change in fair value	(1,426)
Exercise of warrants (Note 10)	(4,018)
ISI acquisition contingent consideration	0
Balance as of September 30, 2020	0
Common Stock Warrant Liability [Member] \| June 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2019	1,993
Change in fair value	(1,064)
Exercise of warrants (Note 10)	0
ISI acquisition contingent consideration	0
Balance as of September 30, 2020	929
Common Stock Warrant Liability [Member] \| September 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2019	2,920
Change in fair value	(1,567)
Exercise of warrants (Note 10)	0
ISI acquisition contingent consideration	0
Balance as of September 30, 2020	1,353
Contingent Liability [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2019	2,000
Change in fair value	0
Exercise of warrants (Note 10)	0
ISI acquisition contingent consideration	280
Balance as of September 30, 2020	$ 2,280

Industrial Seed Innovations Acquisition - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2020 USD ($) Installment Term shares	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) shares	Sep. 30, 2019 USD ($)
Business Acquisition [Line Items]
Revenues	$ 314,000	$ 392,000	$ 904,000	$ 753,000
Existence of option to extend			true
Lease option to extend, description			Some leases (the Davis office, warehouse, greenhouse and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years.
Maximum [Member]
Business Acquisition [Line Items]
Operating leases, term of contract	5 years		5 years
Option to extend lease, term	6 years		6 years
Minimum [Member]
Business Acquisition [Line Items]
Operating leases, term of contract	1 year		1 year
Option to extend lease, term	1 year		1 year
Industrial Seed Innovations [Member]
Business Acquisition [Line Items]
Purchase price consideration	$ 1,212,000
Cash paid for Acquisition	500,000
Business combination, equity interest issuable, value	432,000
Remaining amount paid in multiple installments	280,000
Revenues	$ 0
Operating leases, term of contract	3 years		3 years
Existence of option to extend	true
Lease option to extend, description	The lease was effective upon the execution of the definitive acquisition agreement and has a term of 3 years with the option to renew for three additional 3-year terms.
Number of lease renewal term \| Term	3
Option to extend lease, term	3 years		3 years
Industrial Seed Innovations [Member] \| Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Acquisition related costs	$ 67,000
Industrial Seed Innovations [Member] \| Common Stock [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable, shares \| shares	132,626
Number of annual installment of common stock shares payable \| Installment	2
Industrial Seed Innovations [Member] \| Common Stock [Member] \| Revenue Milestone in 2021 [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone \| shares	132,626		132,626
Industrial Seed Innovations [Member] \| Common Stock [Member] \| Revenue Milestone in 2022 [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone \| shares	132,626		132,626

Industrial Seed Innovations Acquisition - Schedule of Preliminary Allocation of the Purchase Price of ISI Assets Acquired Based on Fair Values (Details)	Sep. 30, 2020 USD ($)
Business Acquisition [Line Items]
Goodwill	$ 301,000
Industrial Seed Innovations [Member]
Business Acquisition [Line Items]
Inventory	511
Intangible assets	400
Goodwill	301
Total consideration allocated	$ 1,212

Variable Interest Entity - Additional Information (Detail)	1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 29, 2012 Owner	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)
Variable Interest Entity [Line Items]
Direct expenses and allocated overhead amount \| $		$ 240,000	$ 340,000	$ 454,000	$ 982,000
Bioceres, S.A. [Member]
Variable Interest Entity [Line Items]
Number of shareholders owning agricultural investment and development cooperative \| Owner	300

Consolidated Joint Venture - Additional Information (Detail)		3 Months Ended	9 Months Ended
	Aug. 09, 2019 Individual	Sep. 30, 2020 USD ($)	Sep. 30, 2020 USD ($)
Schedule Of Equity Method Investments [Line Items]
Restriction percentage of THC at any point during extraction process			0.30%
Value of plants and biomass		$ 1,300,000	$ 1,300,000
Net loss attributable to noncontrolling interest		$ 774,000	$ 1,081,000
Archipelago Ventures Hawaii, LLC [Member] \| Arcadia Biosciences, Inc [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed \| Individual	2
Joint venture interest percentage		50.75%	50.75%
Capital contributions		$ 1,927,000	$ 1,927,000
Archipelago Ventures Hawaii, LLC [Member] \| Legacy Ventures Hawaii, LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed \| Individual	2
Joint venture interest percentage		49.25%	49.25%
Capital contributions		$ 1,871,000	$ 1,871,000

Collaborative Arrangements - Additional Information (Detail)	1 Months Ended
	Aug. 31, 2017
Collaborative Arrangements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contractual agreement month and year	2017-08

Leases - Additional Information (Detail) $ in Thousands	9 Months Ended
Leases - Additional Information (Detail) $ in Thousands	Sep. 30, 2020 USD ($) Lease	Apr. 30, 2020 Lease	Dec. 31, 2019 USD ($)
Lessee Lease Description [Line Items]
Sublease, description of option to extend	lease amendments that provide for additional office space in Davis, CA, and extend the term through April 2025, with one option to renew for an additional five-year term. The Company expects to exercise its options to renew, and in accordance with ASC 842, accounted for the amendment and expected renewal as a lease modification and remeasured the operating lease liability
Number of lease amendments \| Lease	3	2
Operating Lease, Liability	$ 6,274		$ 2,108
Right of use asset	$ 6,013		$ 1,963
Existence of option to extend	true
Lease option to extend, description	Some leases (the Davis office, warehouse, greenhouse and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years.
Minimum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	1 year
Operating leases, term of contract	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	6 years
Operating leases, term of contract	5 years
ASU No. 2016-02 [Member]
Lessee Lease Description [Line Items]
Operating Lease, Liability	$ 3,800
Right of use asset	$ 3,800
Premises And Equipment [Member]
Lessee Lease Description [Line Items]
Operating leases, term of contract	3 years
Molokai, HI, [Member]
Lessee Lease Description [Line Items]
Sublease, description of option to extend	lease amendment for additional parcels of land in Molokai, HI, modified the Molokai office space lease to extend the term by 12 months, and entered into new lease agreements for office equipment, collectively resulting in an additional $0.1 million of operating lease liabilities and right of use assets.
Operating Lease, Liability	$ 100
Right of use asset	$ 100
Woodland, CA and Oregon [Member]
Lessee Lease Description [Line Items]
Sublease, description of option to extend	lease amendment for the land and greenhouse in Woodland, CA, modified the Woodland lease to extend the term by 4 years collectively, and entered into a new lease for the premises and equipment related to the purchase of ISI in Oregon with a three-year term, resulting in an additional $0.5 million of operating lease liabilities and right of use assets.
Operating Lease, Liability	$ 500
Right of use asset	$ 500
Office Space [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	5 years
Office Space [Member] \| Molokai, HI, [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	12 months
Office Space [Member] \| Woodland, CA, [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	4 years

Leases - Schedule of Leases (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Assets
Operating lease assets	$ 6,013		$ 6,013		$ 1,963
Total leased assets	6,013		6,013		1,963
Liabilities
Current - Operating	700		700		611
Noncurrent - Operating	5,574		5,574		1,497
Total leased liabilities	6,274		6,274		$ 2,108
Lease Cost
Net lease cost	$ 358	$ 209	$ 1,017	$ 627
Lease Term and Discount Rate
Weighted-average remaining lease term (years)	5 years 9 months 18 days		5 years 9 months 18 days		2 years 7 months 6 days
Weighted-average discount rate	6.60%		6.60%		7.00%
SG&A and R&D Expenses [Member]
Lease Cost
Operating lease cost	$ 261	177	$ 745	529
Sublease income	(12)	(13)	(34)	(40)
R&D Expenses [Member]
Lease Cost
Short term lease cost	$ 109	$ 45	303	$ 138
SG&A Expenses [Member]
Lease Cost
Short term lease cost			$ 3

Private Placement and Registered Direct Offering - Additional Information (Detail)								1 Months Ended		2 Months Ended	3 Months Ended		9 Months Ended
	Jul. 08, 2020 USD ($) $ / shares shares	May 18, 2020 USD ($) $ / shares shares	Sep. 05, 2019 $ / shares shares	Jun. 12, 2019 $ / shares shares	Jun. 11, 2018 $ / shares shares	Mar. 22, 2018 $ / shares shares	Mar. 19, 2018	Jul. 31, 2020 $ / shares shares	May 31, 2020 $ / shares shares	Sep. 30, 2019 USD ($) shares	Sep. 30, 2020 USD ($) $ / shares shares	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) $ / shares shares	Sep. 30, 2019 USD ($)	Aug. 13, 2020 shares	Jul. 06, 2020 USD ($) shares	Jul. 02, 2020 shares	May 14, 2020 USD ($) shares	Dec. 31, 2019 USD ($) shares
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price \| $ / shares											$ 6.31		$ 6.31
Gross proceeds from warrant exercises													$ 9,372,000	$ 5,269,000
Common stock, issued \| shares											10,832,203		10,832,203						8,646,149
Common stock value issued											$ 51,000		$ 51,000						$ 49,000
Warrant outstanding \| shares											4,450,689		4,450,689
July 2020 Warrant Exercise Transaction [Member]
Class Of Warrant Or Right [Line Items]
Aggregate agent fee paid													$ 178,000
July 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant \| shares											32,071		32,071
Warrants issued, exercise price \| $ / shares											$ 4.969		$ 4.969
Warrants expiration period													5 years 6 months
Offering costs											$ 91,000		$ 91,000
Issuance of placement agent warrants											$ 101,000		101,000
May 2020 Warrant Exercise Transaction [Member]
Class Of Warrant Or Right [Line Items]
Aggregate agent fee paid													$ 478,000
May 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant \| shares											69,617		69,617
Warrants issued, exercise price \| $ / shares											$ 6.125		$ 6.125
Offering costs											$ 116,000		$ 116,000
Issuance of placement agent warrants													$ 215,000
Warrant, exercisable term													5 years
Warrants [Member] \| July 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant \| shares															32,071
Offering costs											400,000		$ 400,000
Warrants [Member] \| July 2020 Private Placement [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant \| shares															641,416
Warrants [Member] \| May 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Offering costs											800,000		800,000
Warrants [Member] \| May 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant \| shares																	69,617
Warrants [Member] \| May 2020 Private Placement [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant \| shares																	1,392,345
March 2018 Warrant Liability [Member]
Class Of Warrant Or Right [Line Items]
Liabilities marked to market value										$ 3,800,000		$ 3,800,000		3,800,000		$ 1,600,000
Additional income (expense) on liabilities													2,200,000	(1,600,000)
Proceeds from issuance of warrants													2,600,000
March 2018 Warrant Liability [Member] \| Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Warrants value											$ 1,600,000		$ 1,600,000
Stock price \| $ / shares											$ 3.81		$ 3.81
March 2018 Warrant Liability [Member] \| Measurement Input, Price Volatility [Member] \| Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate											1.51		1.51
March 2018 Warrant Liability [Member] \| Measurement Input, Risk Free Interest Rate [Member] \| Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate											0.0019		0.0019
June 2018 Warrant Liability [Member]
Class Of Warrant Or Right [Line Items]
Liabilities marked to market value										4,500,000		4,500,000		4,500,000				$ 4,000,000
Additional income (expense) on liabilities												(1,900,000)	$ 1,400,000	(1,800,000)
Proceeds from issuance of warrants													6,800,000
June 2018 Warrant Liability [Member] \| Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Warrants value											$ 4,000,000		$ 4,000,000
Stock price \| $ / shares											$ 4.00		$ 4.00
June 2018 Warrant Liability [Member] \| Measurement Input, Price Volatility [Member] \| Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate											1.40		1.40
June 2018 Warrant Liability [Member] \| Measurement Input, Risk Free Interest Rate [Member] \| Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate											0.0028		0.0028
June 2019 Warrant Liability [Member]
Class Of Warrant Or Right [Line Items]
Liabilities marked to market value										$ 1,600,000	$ 900,000	1,600,000	$ 900,000	1,600,000
Additional income (expense) on liabilities											$ 400,000	(5,300,000)	$ 1,100,000	(4,500,000)
Investors exercised warrants \| shares										1,053,745
Warrant outstanding \| shares											435,830		435,830
September 2019 Warrant Liability [Member]
Class Of Warrant Or Right [Line Items]
Liabilities marked to market value											$ 1,400,000		$ 1,400,000
Additional income (expense) on liabilities											$ 500,000		1,600,000
March 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued \| shares						1,201,634
Warrant issued, shares of common stock called by warrant \| shares						1,282,832
Warrants issued, exercise price \| $ / shares						$ 10.7258
July 2020 Warrant Exercise Transaction [Member]
Class Of Warrant Or Right [Line Items]
Gain (loss) on extinguishment of warrant liability													$ (682,000)
Offering costs																400,000
Common stock value issued																$ 2,400,000
Warrant outstanding \| shares											673,487		673,487
July 2020 Warrant Exercise Transaction [Member] \| Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Warrants value											$ 2,100,000		$ 2,100,000
Stock price \| $ / shares											$ 3.73		$ 3.73
July 2020 Warrant Exercise Transaction [Member] \| Measurement Input, Price Volatility [Member] \| Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate											1.26		1.26
July 2020 Warrant Exercise Transaction [Member] \| Measurement Input, Risk Free Interest Rate [Member] \| Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate											0.0030		0.0030
July 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant \| shares	641,416							641,416
Warrants issued, exercise price \| $ / shares	$ 3.975							$ 3.85
Gross proceeds from warrant exercises	$ 2,600,000
Warrant, exercisable term								5 years 6 months
July 2020 Warrant Exercise Transaction [Member] \| Fair Value May 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Common stock, issued \| shares																641,416
July 2020 Warrant Transaction [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant \| shares	641,416
Warrants issued, exercise price \| $ / shares	$ 3.85
Warrants expiration period	5 years 6 months
Gross proceeds from warrant exercises	$ 2,600,000
Proceeds from issuance of warrants	2,300,000
Offering costs	$ 269,000
June 2018 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant \| shares					1,392,345
Warrants issued, exercise price \| $ / shares					$ 9.94
Warrants expiration period					5 years 6 months
Class of warrant or right number of securities called by warrants or rights, per share \| $ / shares					$ 0.125
May 2020 Warrant Exercise Transaction [Member]
Class Of Warrant Or Right [Line Items]
Gain (loss) on extinguishment of warrant liability													$ 47,000
Offering costs																		800,000
Common stock value issued																		$ 5,600,000
Warrant outstanding \| shares											1,461,962		1,461,962
May 2020 Warrant Exercise Transaction [Member] \| Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Warrants value											$ 4,400,000		$ 4,400,000
Stock price \| $ / shares											$ 3.81		$ 3.81
May 2020 Warrant Exercise Transaction [Member] \| Measurement Input, Price Volatility [Member] \| Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate											1.28		1.28
May 2020 Warrant Exercise Transaction [Member] \| Measurement Input, Risk Free Interest Rate [Member] \| Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate											0.0038		0.0038
May 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant \| shares		1,392,345							1,392,345
Warrants issued, exercise price \| $ / shares		$ 4.90							$ 4.775
Gross proceeds from warrant exercises		$ 6,800,000
Warrant, exercisable term									5 years
May 2020 Warrant Exercise Transaction [Member] \| Fair Value May 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Common stock, issued \| shares																		1,392,345
May 2020 Warrant Transaction [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant \| shares		1,392,345
Warrants issued, exercise price \| $ / shares		$ 4.775
Warrants expiration period		5 years
Gross proceeds from warrant exercises		$ 6,800,000
Proceeds from issuance of warrants		6,200,000
Offering costs		$ 594,000
June 2019 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant \| shares				1,489,575
Warrants issued, exercise price \| $ / shares				$ 5.00
Warrants expiration period				5 years 6 months
Class of warrant or right number of securities called by warrants or rights, per share \| $ / shares				$ 0.125
September 2019 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Warrant outstanding \| shares											725,356		725,356
September 2019 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant \| shares			659,414
Warrants issued, exercise price \| $ / shares			$ 7.52
Warrants expiration period			5 years 6 months
Class of warrant or right number of securities called by warrants or rights, per share \| $ / shares			$ 0.125
March 2018 Private Placement [Member] \| March 2018 Warrant Liability [Member]
Class Of Warrant Or Right [Line Items]
Liabilities marked to market value										$ 3,800,000	$ 800,000	3,800,000	$ 800,000	3,800,000
Additional income (expense) on liabilities											$ 200,000	$ (1,600,000)	$ 2,200,000	$ (1,600,000)
March 2018 Private Placement [Member] \| March 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued \| shares						300,752
Warrant issued, shares of common stock called by warrant \| shares						300,752
Warrants issued, exercise price \| $ / shares						$ 45.75
Warrants expiration period							5 years
June 2018 Offering [Member] \| June 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued \| shares					1,392,345
Stock price \| $ / shares					$ 9.93
June 2018 Offering [Member] \| Securities Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued \| shares				1,489,575
Stock price \| $ / shares				$ 4.91
September 2019 Offering [Member] \| Securities Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued \| shares			1,318,828
Stock price \| $ / shares			$ 7.52

Debt - Additional Information (Detail) - USD ($)				9 Months Ended
Debt - Additional Information (Detail) - USD ($)	Jun. 26, 2020	May 18, 2020	Apr. 16, 2020	Sep. 30, 2020
Promissory Note [Member] \| Paycheck Protection Program [Member]
Debt Instrument [Line Items]
Interest rate			1.00%
Debt instrument, face amount			$ 1,100,000
Debt instrument maturity date			Apr. 16, 2022
Debt instrument, frequency of periodic payment			monthly
Debt instrument, prepayment penalty			$ 0
Debt instrument outstanding amount				$ 1,100,000
Promissory Note [Member[ \| MidFirst Bank [Member]
Debt Instrument [Line Items]
Interest rate		2.50%
Debt instrument maturity date		May 18, 2023
Debt instrument outstanding amount				2,000,000
Line of credit facility initiation date	Jun. 26, 2020
Line of credit facility maximum borrowing capacity	$ 2,000,000
Line of credit facility agreement date		May 18, 2020
Debt instrument interest rate terms		Pursuant to the Loan Agreement, the Note accrues interest, adjusted monthly, at a rate equal to the greater of (i) 3.25% and (ii) the sum of (a) the quotient of the LIBOR Index divided by (one minus the reserve requirement set by the Federal Reserve), and (b) 2.50%.
Promissory Note [Member[ \| MidFirst Bank [Member] \| Restricted Cash [Member]
Debt Instrument [Line Items]
Deposit account				$ 2,000,000
Minimum [Member] \| Promissory Note [Member[ \| MidFirst Bank [Member]
Debt Instrument [Line Items]
Interest rate		3.25%
Maximum [Member] \| Promissory Note [Member[ \| MidFirst Bank [Member]
Debt Instrument [Line Items]
Line of credit facility maximum borrowing capacity		$ 2,000,000
Vehicle Loans [Member]
Debt Instrument [Line Items]
Debt instrument maturity year				2024
Loans				$ 145,000
Vehicle Loans [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Interest rate				7.64%
Vehicle Loans [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Interest rate				8.00%

Debt - Schedule of Maturities of Current and Noncurrent Debt (Detail) $ in Thousands	Sep. 30, 2020 USD ($)
Lessee Disclosure [Abstract]
Remainder of 2020	$ 126
2021	774
2022	285
2023	2,039
2024	29
Total	$ 3,253

Stock-Based Compensation and Warrants - Additional Information (Detail)						1 Months Ended								2 Months Ended	3 Months Ended				6 Months Ended	9 Months Ended
	Feb. 12, 2020 $ / shares shares	Feb. 03, 2020 $ / shares shares	Mar. 28, 2019 shares	May 20, 2015 shares	May 14, 2015	Jul. 31, 2020 $ / shares shares	May 31, 2020 $ / shares shares	Feb. 29, 2020 $ / shares shares	Sep. 30, 2019 $ / shares shares	Aug. 31, 2019 $ / shares shares	Jul. 31, 2019 $ / shares shares	Jun. 30, 2019 $ / shares shares	Apr. 30, 2019 $ / shares shares	Sep. 30, 2019 $ / shares shares	Sep. 30, 2020 USD ($) $ / shares shares	Sep. 30, 2019 USD ($) $ / shares shares	Jun. 30, 2019 $ / shares shares	Sep. 30, 2018	Jun. 30, 2019 $ / shares shares	Sep. 30, 2020 USD ($) IncentivePlan $ / shares shares	Sep. 30, 2019 USD ($) $ / shares shares	Jul. 08, 2020 $ / shares shares	May 18, 2020 $ / shares shares	Dec. 31, 2019 shares	Sep. 05, 2019 $ / shares shares	Jun. 30, 2014 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive plans \| IncentivePlan																				2
Total number of options outstanding															980,883					980,883				661,701
Unrecognized compensation cost related to unvested stock-based compensation grants \| $															$ 1,200,000					$ 1,200,000
Weighted-average remaining recognition period																				2 years 8 months 12 days
Options granted																				491,494	186,571
Stock-based compensation \| $																				$ 1,844,000	$ 1,870,000
Number of warrant to purchase common stock issued															4,450,689					4,450,689
Warrants issued, exercise price \| $ / shares															$ 6.31					$ 6.31
Service Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares													$ 6.18
Warrant issued, shares of common stock called by warrant													45,154
Warrants vesting period													12 months
Warrant, exercisable term													5 years
Stock compensation expense associated with Warrants, term																			1 year
Compensation expense associated with Warrants \| $															$ 145,000	$ 56,000				$ 145,000	$ 100,000
Performance Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares													$ 6.18
Warrant issued, shares of common stock called by warrant													100,000
Warrant, exercisable term													5 years
Exercise Price of Warrants Four Point Nine One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants vesting period		12 months
Warrant, exercisable term		2 years
Stock compensation expense associated with Warrants, term		12 months
Compensation expense associated with Warrants \| $															9,400					28,200
Exercise Price of Warrants Four Point Seven One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares	$ 4.71
Warrant issued, shares of common stock called by warrant	150,000
Warrants vesting period	12 months
Warrant, exercisable term	2 years
Stock compensation expense associated with Warrants, term	12 months
Compensation expense associated with Warrants \| $															135,400					406,200
Exercise Price of Service Warrants Four Point Nine One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares								$ 2.50
Warrant issued, shares of common stock called by warrant								18,350
Warrant, exercisable term								3 years
Compensation expense associated with Warrants \| $															$ 0					$ 36,700
June 2019 Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrant to purchase common stock issued															510,309					510,309
September 2019 Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrant to purchase common stock issued															725,356					725,356
September 2019 Purchase Agreement [Member] \| Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares																									$ 7.52
Warrant issued, shares of common stock called by warrant																									659,414
May 2020 Warrant Exercise Transaction [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrant to purchase common stock issued															1,461,962					1,461,962
May 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares							$ 4.775																$ 4.90
Warrant issued, shares of common stock called by warrant							1,392,345																1,392,345
Warrant, exercisable term							5 years
July 2020 Warrant Exercise Transaction [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrant to purchase common stock issued															673,487					673,487
July 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares						$ 3.85																$ 3.975
Warrant issued, shares of common stock called by warrant						641,416																641,416
Warrant, exercisable term						5 years 6 months
Independent Contractor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares											$ 2.19
Warrant issued, shares of common stock called by warrant											10,000
Independent Contractor [Member] \| Exercise Price of Warrants Four Point Nine One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares		$ 4.91
Warrant issued, shares of common stock called by warrant		10,000
Two Affiliated Third Parties [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares										$ 1.92
Warrant issued, shares of common stock called by warrant										20,000
Placement Agent [Member] \| June 2019 Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares												$ 6.2938					$ 6.2938		$ 6.2938
Warrant issued, shares of common stock called by warrant												74,479					74,479		74,479
Warrant, exercisable term												5 years
Placement Agent [Member] \| September 2019 Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares									$ 9.4781					$ 9.4781		$ 9.4781					$ 9.4781
Warrant issued, shares of common stock called by warrant									65,942					65,942		65,942					65,942
Warrant, exercisable term									5 years
Placement Agent [Member] \| May 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares							$ 6.125
Warrant issued, shares of common stock called by warrant							69,617
Warrant, exercisable term							5 years
Placement Agent [Member] \| July 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares						$ 4.969
Warrant issued, shares of common stock called by warrant						32,071
Warrant, exercisable term						5 years 6 months
Series D Redeemable Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant issued, shares of common stock called by warrant																										63,071
Number of warrants expired			1,759														61,312
Series D Redeemable Convertible Preferred Stock [Member] \| Investor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares																										$ 363.20
Warrant issued, shares of common stock called by warrant																										61,397
Series D Redeemable Convertible Preferred Stock [Member] \| Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares																										$ 268.80
Warrant issued, shares of common stock called by warrant																										1,674
2015 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan															105,036					105,036
Percentage in payroll deductions to acquire shares of common stock					15.00%
Purchase plan offering period					6 months
Employees are able to purchase company's common stock on first trading day of offering period, percentage					85.00%
Issuance of common stock pursuant to employee stock purchase plan																				35,056
Stock-based compensation \| $															$ 12,200	$ 4,300				$ 40,500	$ 6,000
Purchase Agreement [Member] \| March 2018 Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrant to purchase common stock issued															656,454					656,454
Purchase Agreement [Member] \| March 2018 Purchase Agreement [Member] \| Purchase Price of $10.7258 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrant to purchase common stock issued															641,416					641,416
Warrants issued, purchase price of warrants per share \| $ / shares															$ 10.7258					$ 10.7258
Purchase Agreement [Member] \| March 2018 Purchase Agreement [Member] \| Exercise Price of $41.5625 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrant to purchase common stock issued															15,038					15,038
Warrants issued, exercise price \| $ / shares															$ 41.5625					$ 41.5625
Purchase Agreement [Member] \| June 2018 Offering [Member] \| Exercise Price of $12.568 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrant to purchase common stock issued															69,617					69,617
Warrants issued, exercise price \| $ / shares															$ 12.568					$ 12.568
Purchase Agreement [Member] \| June 2019 Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares												$ 5.00					$ 5.00		$ 5.00
Warrant issued, shares of common stock called by warrant												1,489,575					1,489,575		1,489,575
Warrants issued, purchase price of warrants per share \| $ / shares												$ 0.125					$ 0.125		$ 0.125
Warrant, exercisable term												5 years 6 months
Class of warrant or right, issued percentage in connection with common stock sold												100.00%
Investors exercised warrants and purchase shares of common stock														1,053,745
Purchase Agreement [Member] \| September 2019 Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price \| $ / shares									$ 7.52					$ 7.52		$ 7.52					$ 7.52
Warrant issued, shares of common stock called by warrant									659,414					659,414		659,414					659,414
Warrants issued, purchase price of warrants per share \| $ / shares									$ 0.125					$ 0.125		$ 0.125					$ 0.125
Warrant, exercisable term									5 years 6 months
Class of warrant or right, issued percentage in connection with common stock sold									50.00%
July 2019 Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants vesting period											12 months
Warrant, exercisable term											2 years
Stock compensation expense associated with Warrants, term											12 months
Compensation expense associated with Warrants \| $															$ 2,000					$ 10,000
August 2019 Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant, exercisable term										2 years
Warrants issuance date										Aug. 05, 2019
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant, expiration date																				2025-12
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant, expiration date																				2021-07
2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Terms under the plan																				The 2015 Plan became effective in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 shares under the 2006 Plan that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan.
Total number of shares reserved for issuance under plan				154,387											1,047,188					1,047,188
Options vesting period				4 years														2 years
Additional shares authorized for issuance under the plan												120,000
Common stock available for future grant															85,532					85,532
Total number of options outstanding															961,656					961,656
2015 Omnibus Equity Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable period				10 years
2006 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan				10,637
Total number of options outstanding															19,227					19,227

Stock-Based Compensation and Warrants - Summary of Activity Under Stock Incentive Plans (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares Subject to Outstanding, Beginning Balance	661,701
Shares Subject to Outstanding, Options granted	491,494	186,571
Shares Subject to Outstanding, Options Forfeited	(131,849)
Shares Subject to Outstanding, Options Expired	(40,463)
Shares Subject to Outstanding, Ending Balance	980,883
Shares Subject to Outstanding, Vested and expected to vest	965,445
Shares Subject to Outstanding, Exercisable	540,267
Weighted-Average Exercise Price Per Share, Outstanding Beginning Balance	$ 21.60
Weighted-Average Exercise Price Per Share, Options granted	4.32
Weighted-Average Exercise Price Per Share, Options forfeited	6.39
Weighted-Average Exercise Price Per Share, Options expired	48.57
Weighted Average Exercise Price Per Share, Outstanding Ending Balance	13.87
Weighted Average Exercise Price Per Share, Vested and expected to vest	14.03
Weighted Average Exercise Price Per Share, Exercisable	$ 21.51
Aggregate Intrinsic Value, Outstanding Balance	$ 1		$ 305
Aggregate Intrinsic Value, Vested and expected to vest	$ 1

Stock-Based Compensation and Warrants - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail) - Employee Stock Option [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years 3 days	6 years 2 months 26 days	6 years 6 months	7 years 1 month 17 days
Expected volatility	230.00%	99.00%	133.00%	99.00%
Risk-free interest rate	0.38%	1.84%	1.03%	2.05%

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Federal statutory tax rate			21.00%
Effective tax rate	(0.10%)	0.00%	(0.10%)	(0.10%)
Uncertain tax positions	$ 0		$ 0

Commitments and Contingencies - Additional Information (Detail)		3 Months Ended	9 Months Ended
	Dec. 31, 2010 USD ($) Program	Sep. 30, 2020 USD ($) Installment shares	Sep. 30, 2020 USD ($) shares	Dec. 31, 2019 USD ($)	Jun. 15, 2005 USD ($)
Commitments And Contingencies [Line Items]
Other noncurrent liability		$ 2,280,000	$ 2,280,000	$ 2,000,000
Anawah, Inc [Member]
Commitments And Contingencies [Line Items]
Contingent liability	$ 3,000,000				$ 5,000,000
Date of merger and reorganization			Jun. 15, 2005
Restructuring activities, description			As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs
Number of development programs ceased \| Program	3
Number of development programs \| Program	6
Other noncurrent liability		$ 2,000,000	$ 2,000,000
Gain on abandon of technologies			$ 1,000,000
Industrial Seed Innovations [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		3 years	3 years
Remaining amount paid in multiple installments		$ 280,000
Industrial Seed Innovations [Member] \| Common Stock [Member]
Commitments And Contingencies [Line Items]
Number of annual installment of common stock shares payable \| Installment		2
Minimum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		1 year	1 year
Maximum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		5 years	5 years
Maximum [Member] \| Industrial Seed Innovations [Member] \| Common Stock [Member] \| Revenue Milestone in 2021 [Member]
Commitments And Contingencies [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone \| shares		132,626	132,626
Maximum [Member] \| Industrial Seed Innovations [Member] \| Common Stock [Member] \| Revenue Milestone in 2022 [Member]
Commitments And Contingencies [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone \| shares		132,626	132,626

Commitments and Contingencies - Schedule of Minimum Funding Requirements Under Non-Cancelable Agreement (Detail) $ in Thousands	Sep. 30, 2020 USD ($)
Operating Leases Future Minimum Payments Due [Abstract]
Remainder of 2020	$ 500
2021	750
Total	$ 1,250

Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	5,431,572	4,861,652	5,431,572	4,861,652
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	980,883	691,001	980,883	691,001
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	4,450,689	4,170,651	4,450,689	4,170,651

Net Loss per Share - Summary of Computation of Basic and Diluted Net Loss Per Common Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Numerator:
Net loss attributable to common stockholders	$ (6,391)	$ (14,187)	$ (13,553)	$ (22,562)
Denominator:
Weighted average number of common shares outstanding	10,719,618	6,942,612	9,570,259	5,596,545
Basic net loss per share attributable to common stockholders:	$ (0.60)	$ (2.04)	$ (1.42)	$ (4.03)
Numerator:
Net loss attributable to common stockholders	$ (6,391)	$ (14,187)	$ (13,553)	$ (22,562)
Denominator:
Weighted average number of common shares outstanding	10,719,618	6,942,612	9,570,259	5,596,545
Weighted average number of common shares outstanding - diluted	10,719,618	6,942,612	9,570,259	5,596,545
Diluted net loss per share attributable to common stockholders:	$ (0.60)	$ (2.04)	$ (1.42)	$ (4.03)

Related-Party Transactions - Additional Information (Detail)	1 Months Ended			3 Months Ended	9 Months Ended
	Apr. 30, 2020 USD ($) a Lease	Mar. 31, 2020 USD ($) a	Feb. 28, 2019 USD ($) a	Sep. 30, 2020 USD ($) Lease	Sep. 30, 2020 USD ($) Lease	Dec. 31, 2019 USD ($)
Related Party Transaction [Line Items]
Royalty fees due				$ 29,000	$ 29,000	$ 40,000
Number of lease amendments \| Lease	2			3	3
Lease payments				$ 36,000	$ 84,000
Mr. Kevin Comcowich [Member]
Related Party Transaction [Line Items]
Acres of land \| a			10
Operating leases, term of contract			2 years
Rent payments			$ 1,200
Out of pocket costs			126,400
Payments received from contractor			$ 44,000
Amendment [Member] \| Mr. Kevin Comcowich [Member]
Related Party Transaction [Line Items]
Acres of land \| a	15	10
Operating leases, term of contract	2 years	2 years
Number of additional properties under lease agreement	two additional 15-acre parcels	two additional 10-acre parcels
Rent payments	$ 1,200	$ 1,200
John Sperling Foundation [Member]
Related Party Transaction [Line Items]
Royalty fees due				$ 29,000	$ 29,000	$ 40,000

Subsequent Events - Additional Information (Detail) - Verdeca LLC [Member] - Bioceres Crop Solutions [Member] - USD ($)	Dec. 12, 2020	Nov. 12, 2020
Master Transaction Agreement [Member] \| Forecast [Member]
Subsequent Event [Line Items]
Cash receivable from sale of interest in joint venture	$ 5,000,000
Shares of common stock receivable from sale of interest in joint venture	625,000
Pledge and Security Agreement [Member] \| Forecast [Member]
Subsequent Event [Line Items]
Shares of common stock receivable from sale of interest in joint venture	625,000
Subsequent Event [Member] \| Master Transaction Agreement [Member]
Subsequent Event [Line Items]
Cash receivable from sale of interest in joint venture		$ 5,000,000
Shares of common stock receivable from sale of interest in joint venture		1,875,000
Additional cash receivable for transaction expenses and fees		$ 1,000,000
Additional cash receivable from sale of interest in joint venture		$ 2,000,000
Sale of interest in joint venture, description of transaction		BIOX will also pay the Company an additional (i) $1,000,000 payable in five equal monthly payments beginning on December 12, 2020 for transaction expenses and fees and (ii) $2,000,000 payable in four equal quarterly payments with the first payment commencing within thirty days of either BIOX reaching commercial plantings of at least 200,000 hectares of HB4 soybeans or if China approves the HB4 soybean trait for “food and feed”.
Percentage of royalty payments on net revenues		6.00%
Percentage of wheat sales		25.00%
Restricted period on sale or transfer of common stock		180 days
Subsequent Event [Member] \| Maximum [Member] \| Master Transaction Agreement [Member]
Subsequent Event [Line Items]
Technology royalty revenue receivable on trait fees, from sale of interest in joint venture		$ 10,000,000